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PREFACE 
 
It is a fact of Nature that the solid phase of a material may exhibit different 
structures (carbon, silica, ice, etc. as well as very many molecular crystals). In 
addition to different crystal structures called polymorphs, which are characterized 
by long range order, a material may appear as an amorphous solid phase 
characterized by the lack of long range order. Different solid state structures 
manifest themselves in different properties. The formal recognition of the 
phenomenon of crystal polymorphism is generally credited to E. 
Mitscherlich,1even though the existence of different crystal forms of calcium 
carbonate (calcite, vaterite and aragonite) was identified much earlier by M. H. 
Klaproth in 1788.2 
The phenomenon of polymorphism is ubiquitous in the solid state and involves all 
sort of crystalline solids, from purely covalent, where directional sigma bonds 
between atoms are the exclusive interactions (i.e. silica at atmospheric pressure 
can exist as low quartz, high quartz, tridymite and cristobalite), to “purely 
molecular”, where dispersive non-covalent interactions are the only sources of 
stability for the crystal (i.e. S8sulphur exists as α, β and γ phases) and in between 
the plethora of molecular solids formed by all combination of directional and 
semi-directional non covalent interactions coupled with covalent skeletons and/or 
with ionic contributions arising from charge transfer. Each of these crystals may 
show polymorphism, depending on the conditions of investigation, or preparation 
or treatment. 
However, as the scientific and utilitarian interest on the structure-property 
relationships of crystals, especially molecular crystals, expands and attracts new 
adepts from the communities of supramolecular, materials, nanomaterials, 
biomaterials, and theoretical chemists, the term “polymorphism” appears to be too 
specific to account for the breadth of the field. Take a molecule M: beside 
potentially forming single entity polymorphs, M may crystallize with various 
numbers of solvent molecules, M can form co-crystals with a number of partners, 
and these co-crystals may also be solvates, M may forms salts (e.g. when proton 
6 
 
transfer is possible), and these salts may carry solvent molecules in the crystal 
structure, etc..Furthermore, any of these additional crystal forms of M may show 
crystal polymorphism 3i.e. exhibit alternative crystal structures for the same 
chemical composition. 
	  
Figure 1. Scheme of various types of solid forms. 
Solvates and hydrates are crystal forms that have different properties from those 
of the corresponding solvent-free species.4 One can use desolvation/dehydration 
processes to generate new crystal forms of lower solvates/hydrates or of the 
solvent-free crystals.5 
Crystals containing solvent molecules (solvates) are often formed unpredictably. 
Whether a given molecule will precipitate out of a solvent, say water, with one or 
more molecules of water in the unit cell is not foreseeable. Nor is it predictable 
whether the hydrate will be more stable or less stable of the corresponding 
anhydrous forms, or whether other sub- or super-hydrates, let alone non-
stoichiometric hydrates stable over a range of compositions, will be formed. The 
practical consequences of this “uncertainty principle” are enormous as they 
impact on stability, processability, and reproducibility, even transport and 
manufacture conditions, hence on the market potentials, of any chemical species.  
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Co-crystals represent a means to further expand the variability of crystal forms 
and to access new solid-state properties. The great potential of co-crystals resides 
in their different properties (solubility, dissolution rate, melting point, color, etc.) 
with respect to those of the single entity crystals. At the same time the process of 
co-crystal formation does not alter the chemical integrity of the component of 
interest, such as an active pharmaceutical ingredient. In fact, co-crystals are at the 
forefront of the quest for novel crystal forms, mainly, but not only, because of the 
interest in the pharmaceutical field and in all areas where the final products are 
commercialized and utilized in their solid state forms.6 In the academic world co-
crystals are intensively investigated because they provide new insights into the 
mechanisms of recognition, assembly and packing.7The very definition of a co-
crystal is still controversial, because the borderline between solvates, molecular 
salts (e.g. when proton transfer along a hydrogen bond is involved) and molecular 
complexes is somewhat difficult to define.8,9 
However, we can define a co-crystal as a multiple-component crystal in which 
two or more molecules that are solids under ambient conditions coexist through a 
hydrogen bond.10 
Complementary supramolecularsynthons11 that seem to favor formation of co-
crystals are exemplified by carboxylic acid-pyridine12, carboxylic acid- amide 13 
and alcohol-pyridine.14 Co-crystals involving these supramolecular synthons are 
usually synthesized by slow evaporation from a solution containing stoichiometric 
amounts of the components (co-crystal formers); however, sublimation, growth 
from the melt, grinding of two solid co-crystal formers in a ball mill and solvent-
drop grinding (addition of a small amount of suitable solvent to the ground 
mixture to accelerate co-crystallization)15 are also suitable methodologies. 
Co-crystals in the pharmaceutical field offer opportunities to modify the 
properties (solubility, stability, hygroscopicity and dissolution rate) of an API 
without the modification of molecular structure. Furthermore a co-crystal might 
be used to isolate or purify an API during manufacturing and to separate 
enantiomers.16Another application of co-crystals in the pharmaceutical field is due 
to the possibility to obtain pharmaceutical co-crystals involving two or more 
8 
 
APIs6b,17overcoming the problem associated with traditional combination drugs18 
where two or more APIs are produced in a single tablets.19 Multi-API co-crystals, 
in fact, represent unique solid forms of APIs and display physical and chemical 
properties different from their parent APIs. These advantages together with simple 
and convenient preparation methods favor multi-API co-crystals as potential 
combination drugs.20 
The scope of my research project is to produce and characterize new crystalline 
forms of organic compounds, focusing the attention on co-crystals and then 
transferring these notions on APIs to produce co-crystals of potential interest in 
the pharmaceutical field. 
In the first part of this work co-crystallization experiments were performed using 
as building blocks the family of aliphatic dicarboxylic acids HOOC-(CH2)n-
COOH, with n= 2-8. This class of compounds has always been an object of study 
because it is characterized by an interesting phenomenon of alternation of melting 
points: the acids with an even number of carbon atoms show a melting point 
higher than those with an odd one.21 
 
Figure 2. Melting point trend of aliphatic dicarboxylic acids HOOC-(CH2)n-COOH, 
with n= 2-8. 
The acids were co-crystallized with four dipyridyl molecules (formed by two 
pyridine rings with a different number of bridging carbon atoms) through the 
formation of intermolecular interactions N···(H)O. 
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The bases used were (Scheme 1): 4,4’-bipyridine (BPY), 1,2-bis(4-pyridyl)ethane 
(BPA),1,2-(di-4-pyridyl)ethylene (BPE)and1,2-bis(4-pyridyl)propane (BPP). The 
co-crystals obtained by solution synthesis were characterized by different solid-
state techniques to determine the structure and to see how the melting points in 
co-crystals change. 
 
Scheme 1. 
In the second part of this study we tried to obtain new crystal forms of compounds 
of pharmaceutical interest. The APIs studied (Scheme 2) are: O-
desmethylvenlafaxine (ODV), Lidocaine (1), Nalidixic Acid (2) and Sulfadiazine 
(3).  
 
Scheme 2. 
Each API was subjected to Polymorph Screening22 (using the solvents 
summarized in Table 1) and Salt/Co-crystal Screening23experiments to identify 
new crystal forms characterized by different properties. 
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SOLVENT 
DIETHYL ETHER 
DICHLOROMETHANE 
ACETONE 
CHLOROFORM 
METHANOL 
n-HEXANE 
ETHYL ACETATE 
ETHANOL 
ACETONITRILE 
1,2-DIMETHOXYETHANE 
1-PROPANOL 
WATER 
1,4-DIOXANE 
NITROMETHANE 
1-BUTANOL 
2-METHOXY ETHANOL 
p-XYLENE 
DMF 
DMSO 
Table1. Solvents used in experiments of polymorph screening. 
In a typical Salt/Co-crystal Screening the sample was made to react with a co-
former (solid or liquid) through different methods: crystallization by solution, 
grinding, kneading and solid-gas reactions.24 
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Figure 3. Methods used to prepare pharmaceutical co-crystals. 
The co-formers are acids and bases chosen among the ones listed in the 
pharmaceutical handbook of salts on the basis of their properties (solubility, pKa). 
The pKa values are generally reliable indicators of salt formation when the ΔpKa 
(pKa of base – pKa of acid) is greater than 3, and they predict co-crystal 
formation when the ΔpKa is negative, while their predictive power is poor in the 
ΔpKa range 0-3. In this latter range, complexes between acids and bases can still 
form, although they can be salts or co-crystals or can contain shared protons or 
mixed ionization states that cannot be assigned to either category.25 The new 
crystal forms obtained were characterized by different solid state techniques: 	  
Ø X-ray single crystal diffraction (SC-XRD) 
Ø X-ray powder diffraction (XRPD) 
Ø Differential Scanning Calorimetry (DSC) 
Ø Thermogravimetric Analysis (TGA) 
Ø Evolved gas analysis(EGA) 
Ø FT-IR – ATR 
Ø Solid State N.M.R.  
12 
 
 
BASES ACIDS ACIDS 
L-Arginine  Acetic Acid (d=1.05) Oxalic Acid 
CalciumHydroxide Adipic Acid Phosphoric Acid(M=14,65;d=1,689) 
N-methyl-Glucamine L-Aspartic Acid Salicylic Acid 
Imidazole Citric Acid Sebacic Acid 
L-Lysine Formic Acid (99%, d=1,22) Succinic Acid 
MagnesiumHydroxide Fumaric Acid L-Tartaric Acid 
Piperazine  L-Glutamic Acid Glutaric Acid 
PotassiumHydroxide Glycolic Acid Cinnamic Acid 
SodiumHydroxide (0,1 N)  Hippuric Acid Folic acid 
Triethanolamine (85% d=1,124)  Hydrochloric acid (0.1 N) Ascorbic Acid 
NH
3
 (d=0,9)  Maleic Acid Nicotinic Acid 
Diethanolamine(d=1)  L-Malic Acid  
Diethylamine(d=0,704)  Malonic Acid  
Morpholine (d=1)  DL-Mandelic Acid  
Pyrrolidine (d=0,86) DL-Mandelic Acid  
Adenine MethanesulfonicAc (d=1,48)  
Table 2.List of acids and bases used in the Salt/Co-crystal Screening. 
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1. REMARKABLE REVERSAL OF MELTING POINT 
ALTERNATION BY CO-CRYSTALLIZATION 
1.1. Introduction  
 
Co-crystal is an interesting route to change the physical properties of single 
entity crystals, without altering the chemical integrity of the component. 
Although the main interest is in the pharmaceutical field, we would like to 
focus the attention of the reader on a more academic problem.1 
The phenomenon of melting point alternation in n-alkanes and in most end-
substituted n-alkanes has been known for decades.2 Physical properties such as 
solubility and sublimation enthalpy, that are related to the solid state, also 
exhibit an alternating pattern,3 whereas those related to the liquid state show 
monotonic behaviours. There is vast literature on this phenomen, various 
structural models have been put forward to explain the melting point 
alternation in n-alkane derivates.4 Organic di-acids of the type 
HOOC(CH2)nCOOH are also known to show melting point alternation5 
depending on the number of carbon atoms in the chain. The only examples of 
variations in the melting point alternation induced by co-crystallization have 
been reported in a paper by A. Bond et al.,6 in which co-crystals of n-alkyl 
carboxylic acids with pyrazine show a steady increase in their melting 
temperatures for n(CH2) ≥ 5, and in a paper by Callear et al.,7 in which co-
crystals of imidazole derivatives with α,ω-alkanedicarboxylic acids 
(HOOC(CH2)nCOOH, n = 0–6) show a different behaviour in the melting point 
when n(CH2) = 4.  
In the course of our crystal engineering efforts to prepare molecular co-crystals 
and salts by means of mechanical and other non-solution methods, we have 
synthesised and structurally characterized several families of acid-base 
adducts.8 
In particular, in 2003, we reported the first observation of melting point 
alternation in co-crystals.8aIn the course of the investigation of 
mechanochemically prepared hydrogen bonded co-crystals of DABCO 
(N(CH2CH2)3N) and dicarboxylic acids HOOC(CH2)nCOOH (n= 1-7) we 
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noticed that, irrespective of the salt (proton transfer from the acid to DABCO) 
or molecular (no proton transfer) nature of the products, the melting points of 
the even-acid adducts were systematically higher than those of the odd-acid 
adducts.1 
In this project, the melting point behaviour of acid-base pairs was investigated 
for several bases belonging to the family of the dipyridyl molecules, which are 
constituted of two pyridine rings with a different number of bridging carbon 
atoms. The bases are labelled as BPA(1,2-bis(4-pyridyl)ethane), BPP (1,2-
bis(4-pyridyl)propane), BPY (4,4’-bipyridine) and BPE (1,2-(di-4-
pyridyl)ethylene), see Scheme 1, and we refer to the diacids by the total 
number of carbon atoms in the molecule (C4 corresponding to succinic acid, 
C5 to glutaric acid, etc.), hence the adducts are identified as BPA C4 ÷ BPA
C10, BPP C4 ÷ BPP C10, BPY C4 ÷ BPY C10 and BPE C4 ÷ BPE. 
 
Scheme 1 
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1.2. Experimental 
 
All reactants and solvents were purchased from Sigma Aldrich and used 
without further purification. 
1.2.1. Solution syntheses of BPA Cn (n = 4-10), BPP Cn (n = 4,5,7,8,9,10), 
BPY Cn (n = 4,5,6,7,9,10), BPE C7 
 
Crystalline powder and single crystals were obtained by reaction in methanol 
solution. The reagents (0.5mmol of acid and 0.05mmol of base) were added to 
ca. 10-15 mL of methanol,  the solution was heated until complete dissolution 
and left to evaporate slowly at ca. 4°C. 
1.2.2. Solution synthesis of BPP C6 
 
Crystalline powder and single crystals were obtained by reaction in water 
solution. The reagents (0.5mmol of acid and 0.05mmol of base) were added to 
ca. 10-15 mL of bidistilled water,  the solution was heated until complete 
dissolution and left to evaporate slowly at ca. 4°C. 
1.2.3. Solution synthesis of BPY C8 
 
Crystalline powder and single crystals were obtained by reaction in ethanol 
solution. The reagents (0.5mmol of acid and 0.05mmol of base) were added to 
ca. 10-15 mL of ethanol,  the solution was heated until complete dissolution 
and left to evaporate slowly at ca. 4°C. 
1.2.4. Solution syntheses of BPE Cn (n = 4, 5, 6, 8, 9, 10) 
 
Crystalline powder and single crystals were obtained by reaction in acetone-
ethanol solution. The reagents (0.5mmol of acid and 0.05mmol of base) were 
added to ca. 10-15 mL of a mixture acetone-ethanol (2-1), the solution was 
heated until complete dissolution and left to evaporate slowly at ca. 4°C. 
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1.2.5. Differential Scanning Calorimetry (DSC) 
 
Differential scanning calorimetry was used to measure the melting point of all 
compounds and to detect the presence of additional crystalline phases. In some 
cases solid-solid phase transitions to higher temperature polymorphs were also 
observed before melting (BPA·C6,  133 °C (onset), BPA·C8, 131 °C (onset), 
BPA·C9, 123 °C (onset).  
Calorimetric measurements were performed using a Perkin Elmer Pyris 
Diamond DSC differential scanning calorimeter equipped with a model ULSP 
90 intra-cooler. The instrument was calibrated with high-purity standards 
(indium and cyclohexane) at 5 K min-1. The samples (2–4 mg) were placed in 
aluminium closed pans, and heating was carried out at 5°C min–1 .  
1.2.6. X-Ray diffraction 
 
Single-crystal data were collected on an Oxford X’Calibur S CCD 
diffractometer equipped with a graphite monochromator (MoKα radiation, λ = 
0.71073) and operated at room temperature. The structures were solved by 
direct methods and refined by full-matrix least-squares on F2 with SHELX979a 
program package.  
A calculated XRPD pattern was generated for Cu radiation using Mercury v 
1.4 or. PowderCell 2.29dand the atomic coordinates, space group, and unit cell 
parameter from the single crystal data. 
MERCURY and SCHAKAL99 9b were used for the graphical representation of 
the results and PLATON 9c was used for hydrogen bonding analysis. 
X-ray powder diffractograms were collected on a Panalytical X’Pert Pro 
automated Diffractometer equipped with X’Celerator, CuKα, using a glass 
sample holder. The tube voltage and amperage were set to 40 kV and 40 mA, 
respectively. The program used for data collection was set to record only the 
data points within the 2θ range 3 – 40 deg. 
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1.2.7. Solid-state Nuclear Magnetic Resonance (SS NMR) spectroscopy 
 
SS NMR experiments were recorded on a Bruker Avance II 400 instrument. The 
spectra were collected and interpretated by the Research Group of Prof. Roberto 
Gobettoo at the University of Torino. 
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1.3. Results and discussion 
 
In this project, the melting point behaviour of acid-base pairs was investigated 
for several bases belonging to the family of the dipyridyl molecules, which are 
constituted of two pyridine rings with a different number of bridging carbon 
atoms. 
All co-crystals  have been investigated by a combination of solid state 
techniques, namely single crystal [except for: BPY·Cn(n=5, 6, 7, 10), 
BPE·Cn(n=4, 6), BPP·C4, whose structures were already known10, and 
BPY·C9, BPP·Cn(n=8, 9), BPE·Cn(n=7, 9, 10) for which no good single 
crystals were obtained] and powder X-ray diffraction, differential scanning 
calorimetry and solid-state NMR spectroscopy (SS NMR). 
This latter in particular has been instrumental not only to the definition of the 
nature of the crystals, whether molecular or salts, resulting from the 
positioning of the acid protons in the O···H···N interactions,8a,11 but also to the 
definition of the packing features in the adducts (BPP Cn), for which no single 
crystal X-ray data could be obtained.  
All compounds were crystallized by slow evaporation from different solvents. 
Correspondence between the structures determined by single crystal X-ray 
diffraction and those of the bulk materials was checked by comparing 
calculated and measured powder patterns (See supplementary material). All 
compounds are characterized by the presence of infinite chains constituted of 
alternating base and acid units (Figure 1 and Figure 2), joined together via 
N···(H)O and C(H)···O hydrogen bonds in the series with BPA and 
BPP.Crystal data and details of measurements are summarized in Table 1, 
Table 2 and Table 3. Relevant hydrogen bonding distances (in Å) for all the 
compounds structurally characterized in this chapter are summarized in Table 
4. 
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Figure 1. N···(H)O hydrogen bonded chains of base and acid units in (from top to 
bottom) crystalline BPA·C4, BPA·C5, BPA·C6, BPA C7, BPA C8, BPA C9, BPA 
C10. 
  
BPA-­‐C4
BPA-­‐C5
BPA-­‐C6
BPA-­‐C7
BPA-­‐C8
BPA-­‐C9
BPA-­‐C10
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Figure 2. N···(H)O hydrogen bonded chains of base and acid units in (from top to 
bottom) crystalline BPY·C4, BPY·C8, BPE·C5, BPE C8, BPP C5, BPP C6, BPP C7, 
BPP C10. 
  
BPY-­‐C4
BPY-­‐C8
BPE-­‐C5
BPE-­‐C8
BPP-­‐C5
BPP-­‐C6
BPP-­‐C7
BPP-­‐C10
BPP-C10 
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Table 1. Crystal Data and Details of Measurements for compounds BPY·C4, BPY·C8, 
BPE·C5 and BPE·C8. 
compound BPY C4 BPY C8 BPE C5 BPE C8 
Formula C14H14N2O4 C18H22N2O4 C17H18N2O4 C20H22N2O4 
Mr 274.27 330.38 314.34 354.22 
system Triclinic Triclinic Monoclinic Triclinic 
space group P-1 P-1 C2/c P-1 
a [Å] 7.3603(6) 8.9882(5) 15.750(3) 5.8000(3) 
b [Å] 9.2459(8) 9.6220(5) 10.3012(1) 8.8127(4) 
c [Å] 11.0608(9) 11.2238(4) 9.5812(1) 9.5299(5) 
α  [°] 98.951(7) 81.035(4) 90.00 76.389(4) 
β  [°] 106.043(7) 72.146(5) 90.393(1) 89.748(4) 
γ[°] 110.453(7) 65.971(5) 90.00 76.804(4) 
V [Å³] 650.68(9) 843.33(7) 1554.5(4) 460.30(4) 
Z 2 2 4 1 
dcalc[g mm-3] 1.4 1.301 1.343 1.278 
F(000) 288 352 664 188 
µ(MoKα) [mm-
1] 
0.104 0.092 0.097 0.090 
θmax [°] 25 28.88 24.63 29.09 
measuredreflns 4513 7764 2077 10063 
uniquereflns 2203 3785 973 2202 
refined 
parameters 
189 225 109 118 
GOF on F² 1.204 1.143 1.223 1.064 
R1 [on F, 
I>2σ(I)] 
0.0860 0.0901 0.0557 0.0540 
wR2(onF²,all 
data) 
0.1648 0.1768 0.1652 0.1340 
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Table 2. Crystal Data and Details of Measurements for compounds BPA·C4 to BPA·C10 
compound Succinic 
acid 
1C4 
Glutaric 
acid 
1C5 
Adipic acid 
1C6 
Pimelic acid 
1C7 
Suberic acid 
1C8 
Azelaic acid 
1C9 
Sebacic acid 
1C10 
Formula C16H18N2O4 C17H20N2O4 C18H22N2O4 C19H24N2O4 C20H26N2O4 C21H28N2O4 C22H28N2O4 
Mr 302.32 316.35 330.38 344.40 358.43 372.45 384.46 
system Monoclinic Monoclinic Triclinic Monoclinic Monoclinic Monoclinic Triclinic 
space group C2/c P21/c P -1 P21/c P21/c C2/c P-1 
a [Å] 21.121(2) 12.2889(4)  7.2159(6) 11.138(1) 11.6701(5) 10.656(3) 6.9363(4)  
b [Å] 4.9224(3) 11.1400(5)  7.3354(7) 47.332(5) 20.9348(7) 8.429(1)  6.9574(4)  
c [Å] 16.6376(1) 24.3454(1) 8.8449(7) 14.436(2) 12.9988(5) 22.310(2) 12.0029(8) 
α  [°] 90.00 90.00 90.210(7) 90.00 90.00 90.00 77.230(5) 
β  [°] 119.752(6) 96.933(4) 93.428(6) 105.832(1) 114.656(5) 99.851(4) 73.739(6) 
γ[°] 90.00 90.00 115.808(9) 90.00 90.00 90.00 71.192(6) 
V [Å³] 1501.7(2) 3308.5(2) 420.49(6) 7322(1) 2886.2(2) 1974.3(6) 520.90(5) 
Z 4 8 1 16 6 4 1 
dcalc 1.337 1.270 1.305 1.250 1.137 1.253 1.226 
F(000) 640 1344 176 2944 1152 800 206 
µ(MoKα)  [mm-1] 0.097 0.091 0.093 0.088 0.086 0.087 0.084 
θmax [°] 29 28 29 28 28.4 25 29 
measuredreflns 3714 18988 4004 60898 13402 1768 4579 
uniquereflns 1728 7286 1907 16573 6159 1720 2332 
refined parameters 104 427 112 934 365 127 144 
GOF on F² 0.954 0.900 0.916 0.986 1.035 1.006 0.862 
R1 [on F, I>2σ(I)] 0.0427 0.0827 0.0499 0.0827 0.0793 0.0424 0.0545 
wR2(onF²,all data) 0.1136 0.2049 0.1370 0.2987 0.2062 0.1291 0.1505 
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Table 3. Crystal Data and Details of Measurements for compounds BPP·C5, BPP·C6, 
BPP·C7 and BPP·C10 
compound BPP C5 BPP C6 BPP C7 BPP C10 
Formula C18H22N2O4 C19H24N2O4 C20H26N2O4 C23H32N2O4 
Mr 330.38 344.4 358.43 400.51 
system Monoclinic Monoclinic Triclinic Monoclinic 
space group P21/c C2/c P-1 C2/c 
a [Å] 5.43048(2) 13.7629(8) 7.1246(4) 12.661(3) 
b [Å] 20.7179(7) 5.3869(4) 11.1403(4) 10.129(1) 
c [Å] 15.4813(6) 24.640(2) 12.9265(7) 17.361(2) 
α  [°] 90.00 90.00 81.099(4) 90 
β  [°] 92.205(3) 95.597(6) 84.868(5) 93.13(1) 
γ[°] 90.00 90.00 71.717(4) 90 
V [Å³] 1740.6(1) 1818.1(2) 961.54(8) 2223.1(6) 
Z 4 4 2 4 
dcalc[g mm-3] 1.261 1.258 1.238 1.197 
F(000) 704 736 384 864 
µ(MoKα)  [mm-
1] 
0.090 0.089 0.086 0.082 
θmax [°] 26 25 26 25 
measuredreflns 15427 4312 7249 5603 
uniquereflns 3411 1586 3687 1935 
refined 
parameters 
239 114 243 132 
GOF on F² 1.159 1.099 0.911 1.023 
R1 [on F, 
I>2σ(I)] 
0.0882 0.0647 0.0580 0.0934 
wR2(onF²,all 
data) 
0.1685 0.1429 0.1333 0.2667 
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Table 4.  Relevant hydrogen bonding distances (in Å) for all the compounds structurally characterized in this paper 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) N···O < 3.0 Å ; b) C···O < 3.5 Å 
compound BPY C4 --- --- --- BPY C8 --- --- 
N···(H)Oa 2.629(4)    2.675(4) 
2.658(4) 
  
C(H)···Ob ---    ---   
compound BPA C4 BPA C5 BPA C6 BPA C7 BPA C8 BPA C9 BPA C10 
N···(H)Oa 2.607(2) 2.650(4) 
2.631(5) 
2.656(5) 
2.649(5) 
2.613(2) 2.611(4) 
2.642(4) 
2.629(4) 
2.633(4) 
2.643(4) 
2.645(3) 
2.629(3) 
2.620(3) 
2.653(2) 2.654(2) 
C(H)···Ob 3.345(3) 3.295(6) 
3.272(6) 
3.330(2) 3.195(6) 
3.294(6) 
3.190(5) 
3.250(5) 
3.239(6) 
3.245(5) 
3.258(5) 
3.336(4) 
3.238(3) 
3.437(4) 
3.413(2) 3.355(3) 
compound --- BPE C5 --- --- BPE C8 --- --- 
N···(H)Oa  2.616(4)   2.670(2)   
C(H)···Ob  ---   ---   
compound --- BPP C5 BPP C6 BPP C7 --- --- BPP C10 
N···(H)Oa  2.624(3) 
2.653(3) 
2.676(3) 2.645(3) 
2.644(3) 
  2.660(5) 
C(H)···Ob  3.321(4) 
3.467(4) 
3.334(4) 
3.290(3) 3.269(3) 
3.436(3) 
3.346(3) 
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Table 5 and Figure 3 collect all information on the melting points as 
determined by differential scanning calorimetry. The melting points of the 
dicarboxylic acids6 are also reported for comparison. 
 
Table 5.Melting points (°C) for pure diacids6 and co-crystals (n is the total number of C 
atoms in the acid). 
a) The DSC trace shows also the presence of an endothermic solid-to-solid phase transition at 
lower temperature (see ESI); b) Sigma-Aldrich; c) Alfa Aesar,  d) Fluka. 
 
Figure 3.Melting point alternation for pure acids, BPY·Cn, BPA·Cn,BPE·Cn and 
BPP·Cn series (n in the range 4 to 10 corresponding to succinic, glutaric, adipic, pimelic, 
suberic, azelaic and sebacic, respectively). 
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280	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   5	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   7	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p 
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) 
Total number of C atoms in the dicarbxylic acid 
MP(°C)ACIDS 
MP(°C)ACID-BPY 
MP(°C)ACID-BPA 
MP(°C)ACID-BPE 
MP(°C)ACID-BPP 
Cn pure 
acid 
BPY·Cn  BPA·Cn  BPE·Cn BPP·Cn pure base 
C4 188 229.18 169.3 261.83 155.8  
C5 99 145.33 134.2 192.75 131.3  
C6 153 174.32 173.7a 213.28 112.6  
C7 106 141.1 145.1 156.68 138.1  
C8 144 178.72 180.9a 183.49 110.8  
C9 106 137.1 131.1a 143.08 131.1  
C10 134.5 168.58 160.1a 169.31 101.1  
      BPY 110-114b 
      BPA 110-112b 
      BPE 148-152d 
      BPP 53-56c 
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Figure 3 allows the following observations: i) the melting points of the co-
crystals with BPY, BPA and BPE, except for BPA·C4, are invariably higher 
than those of the starting dicarboxylic acids and of the co-crystals with BPP; 
ii) the co-crystals with BPY, BPA and BPE follow the same alternating trend 
as the diacids i.e. higher melting points are shown by the co-crystals with even 
carbon atom chains (succinic, adipic, suberic, and sebacic); iii) the co-crystals 
with BPY and BPA have very similar melting points except for the co-crystals 
of BPA·C4and BPA·C5that show a melting point lower than those with BPY; 
iv) the co-crystals of BPE with C8, C9 and C10 present a very close melting 
point to those with BPY and BPA; v) the co-crystals with BPP present an 
inverse trend, i.e. higher melting points are shown by the co-crystals with 
glutaric, pimelic and azelaic acid thus demonstrating that it is the overall 
number of carbon atoms in the repeating units along the hydrogen bonded 
chains that matters, irrespective of the supramolecular nature of the 
interactions within such repeating unit; vi) an exception to this behaviour is 
represented by the co-crystal BPP·C4 (succinic acid) which shows a melting 
point of ca. 156°C, still lower than that of the corresponding succinic acid 
itself, but higher than that of BPP C5.It is also interesting to note that the 
difference in the melting points of BPY (110-114°C), BPA (100–110°C), BPE 
(148-152°C) and BPP (57–60°C) is somehow reflected in the fact that, on 
average, the melting points for the BPY·Cn, BPA·Cn and BPE·Cn co-crystals 
are higher than those of the BPP·Cn co-crystals. It can be seen that for co-
crystals with BPY, BPA and BPE the trend is comparable to those of pure 
dicarboxylic acids HOOC(CH2)nCOOH (n = 2-8). 
SS NMR spectroscopy has been able to detect the similarity of all structures in 
terms of the main packing feature, i.e. chains of alternating base and acid 
units; in addition to this, it shows that the melting point alternation is 
consistent with the length of the chain repeating unit rather than on 
conformational features or global crystal packing.12 The co-crystal nature of all 
the adducts has been ascertained by means of 13C  and in some case (BPA and 
BPP series)15N CPMAS NMR spectra (spectra 15N and chemical shifts are 
reported in ESI Figures and Tables). Both sets of data confirm that no proton 
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transfer took place in any adducts: the 13C carboxylic chemical shifts (around 
175-178 ppm) are typical of COOH rather than COO- groups and the 15N 
pyridine chemical shifts for BPA and BPP adducts (around 250-260 ppm) are 
in the region of the pyridine rather than the pyridinium anion.13 Numbers and 
relative intensities of COOH and N signals in each spectrum are in agreement 
with the presence in the unit cell of different carboxylic and pyridine 
environments (See supplementary material).  
The presence and strength of a hydrogen bond can be evaluated with 1HMAS 
SS NMR spectra. Indeed, the signals of hydrogen atoms involved in hydrogen 
bonds are at high values of chemical shift, away from the aliphatic and 
aromatic regions. Moreover, since its chemical shift depends on the 
polarization of the XH covalent bond, the stronger the interaction, the greater 
the polarization of the bond and the higher the value of chemical shift14(Figure 
4). 
 
Figure 5:Strengthof thehydrogen bondinan1HNMRspectrum. 
 
The 1H hydrogen bond signals are summarized in Table 6 and the comparison of 
all spectra of the four co-crystals series is shown in supplementary material. 
13C ACID-BPY ACID-BPE ACID-BPA ACID-BPP 
Succinic 15.7 15.8 16.7 16.3 
Glutaric 14.9 15.5 16.4-14.7a 15.4 
Adipic 14.9 15.4 16.9 14.6 
Pimelic 14.4 14.9 16.0 16.2 
Suberic 14.6 14.3 16.4 16.1 
Azelaic 15.0 14.6 15.2 16.3 
Sebacic 15.0 14.4 15.5 15.0 
Table6: 1Hchemical shift data (ppm) of co-crystals series with BPY, BPA, BPE and BPP. 
a) In agreement with the presence of various N···O environments. 
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For each set of co-crystals, the comparison between the hydrogen bond 1H 
chemical shift and the melting points reported in figure 7 shows the following 
features: i) in the co-crystals with BPY the chemical shift  trend follows that of 
the melting points but for sample C9 BPY; ii) in the co-crystals with BPE the 
chemical shift trend does not follow that of the melting points but it is observed 
that an overall decrease in the melting points, increasing the length of  acid chain, 
corresponds to a decrease in  the strength of hydrogen bonds and in the1H 
chemical shift values; iii) in the co-crystals with BPA and BPP the chemical shift 
trend strictly resembles the melting point behaviour, furthermore, a low-frequency 
shift is observed by increasing the acid chain length in agreement with N···O (See 
supplementary material) distances and with the previously reported dicarboxylic 
acid-dabco series.8a,15 
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Figure 7:Comparison between melting points trend and chemical shift trend for each set of co-crystals.
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1.4. Conclusion 
 
In summary, we have shown that the melting point alternation phenomenon 
propagates also via hydrogen bonding interactions. Our experiments with the 
co-crystals of the dicarboxylic acids with BPA and BPP16indicate that it is the 
sum of the carbon atoms in the repeating unit that correlates with the melting 
points measured on these two classes of compounds, and the reason for the 
alternation has to be found in the number and type of hydrogen bonding 
intermolecular interactions, responsible for packing efficiency and thus for 
lattice energy; we have also provided further evidence on the molecular nature 
of crystals in cases where the difference depends solely on the positioning of 
the proton along an H-bond,17 and does not affect a bulk physical property of 
solid materials such as the melting point. The hydrogen bond strength, on the 
other hand, seems to be one the parameters influencing this physical property 
since, at least from an NMR point of view, the highest melting points are 
associated in most cases to strong hydrogen bond interactions and vice versa. 
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1.5. Supplementary Material 
 
------------------------------------------------------------------------------------- 
Legenda 
 
BPY C4 = BPY-Succinic Acid  BPAC4 = BPA-Succinic Acid 
BPY C5 = BPY-Glutaric Acid  BPAC4 = BPA-Succinic Acid 
BPY C6 = BPY-Adipic Acid   BPAC4 = BPA-Succinic Acid 
BPY C7 = BPY-Pimelic Acid  BPAC4 = BPA-Succinic Acid 
BPY C8 = BPY-Suberic Acid  BPAC4 = BPA-Succinic Acid 
BPY C9 = BPY-Azelaic Acid  BPAC4 = BPA-Succinic Acid 
BPY C10 = BPY-Sebacic Acid  BPAC4 = BPA-Succinic Acid 
 
BPEC4 = BPY-Succinic Acid  BPPC4 = BPA-Succinic Acid 
BPEC5 = BPY-Glutaric Acid  BPPC4 = BPA-Succinic Acid 
BPEC6 = BPY-Adipic Acid   BPPC4 = BPA-Succinic Acid 
BPEC7 = BPY-Pimelic Acid   BPPC4 = BPA-Succinic Acid 
BPEC8 = BPY-Suberic Acid   BPPC4 = BPA-Succinic Acid 
BPEC9 = BPY-Azelaic Acid   BPPC4 = BPA-Succinic Acid 
BPEC10 = BPY-Sebacic Acid  BPPC4 = BPA-Succinic Acid 
 
--------------------------------------------------------------------------------------------------- 
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1.5.1. Thermal behavior – BPY 
 
Differential scanning calorimetry measurements for the BPY·C4, 
BPY·C5,BPY·C6, BPY·C7, BPY·C8, BPY·C9 and BPY·C10 adducts.  
 
 
 
BPY··C4 
BPY··C5 
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BPY··C10 
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1.5.2. Thermal behavior - BPA 
Differential scanning calorimetry measurements for the BPA·C4, 
BPA·C5,BPA·C6, BPA·C7, BPA·C8, BPA·C9 and BPA·C10 adducts.  
 
 
 
 
 
BPA··C4 
BPA··C5 
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1.5.3. Thermal behavior – BPE 
 
Differential scanning calorimetry measurements for the BPE·C4, 
BPE·C5,BPE·C6, BPE·C7, BPE·C8, BPE·C9 and BPE·C10 adducts.  
 
 
 
BPE·C4 
BPE·C5 
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1.5.4. Thermal behavior – BPP 
 
Differential scanning calorimetry measurements for the BPP·C4, 
BPP·C5,BPP·C6, BPP·C7, BPP·C8, BPP·C9 and BPP·C10 adducts.  
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1.5.5. XRPD Patterns - BPY:acid 
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1.5.6. XRPD Patterns - BPA:acid 
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1.5.7. XRPD Patterns - BPE:acid 
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1.5.8. XRPD Patterns - BPP:acid 
5 10 15 20 25 30 35 40
	  E xp
	  C a lc
2θ /deg
 
5 10 15 20 25 30 35 40
	  C a lc 	  
	  E xp
2θ	  /deg
 
  
BPP C5 
BPP C6 
57 
 
10 20 30 40
	  C a lc
	  E xp
2θ	  /deg
 
5 10 15 20 25 30 35 40
2θ /deg  
BPP C7 
BPP C8 
58 
 
5 10 15 20 25 30 35 40
2θ /deg  
10 20 30 40
	  C a lc
	  E xp
2θ	  /deg
 
  
BPP C9 
BPP C10 
59 
 
1.5.9. Solid-state NMR 
 
The spectra were collected and interpretated by the Research Group of Prof. 
Roberto Gobetto of Torino University. 
The chemical shift of pure dicarboxylic acids are slightly higher than the 
average value of a COOH group. This is because they form the typical cyclical 
centrosymmetric dimerization of carboxyl function which creates a resonance 
between the bond sleading to an intermediate chemical shift value between 
carboxylic and carboxylate. 
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Figure 1:13C CPMAS NMR spectra of the co-crystals series with BPY, BPA, BPE and 
BPP recorded with a spinning speed of 12 kHz. 
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Figure 2: 15N CPMAS NMR spectra of the acid-BPA and acid-BPPseries recorded with a 
spinning speed of 6 kHz. 
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Figure 3:1H MAS NMR spectra of the co-crystals series with BPY, BPA, BPE and BPP 
recorded with a spinning speed of 32 kHz. 
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2. CRYSTAL FORMS OF THE NOVEL OXALATE SALT OF  
O-DESMETHYLVENLAFAXINE  
2.1. Introduction 
 
The pharmaceutical industry relies predominantly on solid, possibly crystalline 
forms for the delivery of active pharmaceutical ingredients (APIs), mainly for 
reasons of purity, thermal stability, manufacturability, and ease of handling. 
However, problems associated with the solid form of many drugs exist, 
including polymorphic conversion, low solubility, and low bioavailability for 
crystalline solids, and the tendency of amorphous forms to spontaneously 
crystallize into more stable crystalline forms.1 For these reasons, but also for 
the considerable financial interests caused by legal ramifications, a constant 
screening for new drug solid forms, including salts, solvates and co-crystals, is 
ongoing.2 More than 50% of the drugs on the market today are sold as organic 
salts3. The interest in salt formation has grown greatly over the past decades 
and, in recent years, it has become the most commonly used technique to 
improve the property of an API4. Salification of a drug substance, a crucial 
step in drug development, can have a huge impact on its properties, including 
solubility, dissolution rate, hygroscopicity, stability, impurity profile and 
particle characteristics5. The investigation of crystal forms represents 
nowadays a large portion of the experimental and theoretical work in the 
domain of crystal engineering, with considerable ramifications in different 
areas of solid state chemistry6. 
O-Desmethylvenlafaxine is a selective serotonin and norepinephrine reuptake 
inhibitor useful for the treatment of depression. The fumarate salt of O-
Desmethylvenlafaxine is known and has poor physiochemical and permeability 
characteristics (See US Patent 4,535,186). US Patent 7,291,347 discloses that 
the succinate salt of O-Desmethylvenlafaxine has a much more improved 
solubility as compared to the fumarate salt and thus has improved 
bioavailability. It is reported to exist in four crystalline forms one of which is a 
monohydrate form characterized by single crystal X-ray diffraction7. In the 
course of our studies we discovered a new salt of O-Desmethylvenlafaxine, 
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oxalate salt (WO 2009/155488 A2), with similar stability and significantly 
improved solubility compared with the fumarate and succinate salts of O-
Desmethylvenlafaxine (ODV). The new salt is labelled as ODV-OX (Scheme 
1). 
 
Scheme 1. Structure of ODV-OX (0 › n ‹ 2.5). 
  
n 
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2.2. Experimental section 
2.2.1. Synthesis of ODV 
 
The synthesis of ODV is taken from the patent US 2008/0015259 A1.  
4 g of Venlafaxine were dissolved in 10 mL of N-methyl-pirrolidone with 2 g 
of Na2S in N2 atmosphere. The N2 flux was closed and solution was heated to 
175°C in 1 hr. The solution was left at 175°C for 3 hrs and after was cooled to 
90°C. 12 mL of water were added to solution that after was cooled at room 
temperature and left at 4°C for approx. 12 hrs. The suspension was filtered and 
washed with water. 
2.2.2. Solution synthesis of ODV-OX Form A 
 
ODV-OX Form A was prepared dissolving 4 mmol of Des-Methyl-
Venlafaxine and 4 mmol of Oxalic acid (stoichiometric ratio 1:1) in 4 mL of 
boiling water. The solution,concentrated and purified by filtration, was left to 
evaporate at 60°C or room temperature. 
2.2.3. Solution synthesis of ODV-OX Form B 
 
ODV-OX FORM B was obtained by dissolving 0.200 g of ODV-OX Form A 
in 2 mL of Acetone. The suspension was left under stirring for three days at 
room temperature and filtered on a Whatman filter. 
2.2.4. Solution synthesis of ODV-OX Form C 
 
ODV-OX FORM C was obtained by evaporation of an acetonitrile solution of 
ODV-OX FORM A. The solution was prepared dissolving 0.05 g of ODV-OX 
Form A in 4mL acetonitrile. The solution was left under stirring at room 
temperature, filtered with a Whatman filter and left to evaporate at 60°C. 
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2.2.5. Solution synthesis of ODV-OX Form D 
 
ODV-OX FORM D was obtained by evaporation of a water solution of ODV-
OX FORM A. The solution was prepared dissolving 0.05 g of ODV-OX Form 
A in 4 mL water. The solution was left under stirring at room temperature, 
filtered with a Whatman filter and left to evaporate at 4°C. Single crystal of 
Form D was obtained. 
2.2.6. Solution synthesis of ODV-OX Form E 
 
ODV-OX Form E was obtained by dissolving 1 g of ODV-OX in 15 mL of 1-
Propanol. The suspension was stirred for seven days at room temperature, and 
filtered on a Whatman filter. The sample was dried at 90-100 degrees for 1 hrs. 
2.2.7. Solution synthesis of ODV-OX Form F (Form B-100D in the Patent 
WO 2009/155488 A2) 
 
ODV-OX FORM F was obtained by dissolving 0.200 g of ODV-OX FORM A 
in 2 mL of acetone. The suspension was stirred for three days at room 
temperature, and filtered on a Whatman filter. The sample was dried at 90-100 
°C for 1 hrs.  
2.2.8. Thermal behaviour  
 
Thermogravimetric analyses were performed using a simultaneus STA 409 PC 
Luxx® Netzsch equipped with a thermocouple for the direct measurament of 
DSC signal, and a thermobalance for the measurament of TGA signal. The 
samples (5-15 mg) were placed in aluminium pierced pans, and the heating 
was carried out at 10°C min–1 in N2 atmosphere (See supplementary material). 
Calorimetric measurements were performed using a DSC 200 F3 Maia® 
differential scanning calorimeter equipped with an intra-cooler. The samples 
(2–4 mg) were placed in aluminium pierced pans, and the heating was carried 
out at 10°C min–1 in N2 atmosphere(See supplementary material). 
69 
 
2.2.9. X-Ray diffraction 
 
Single-crystal data were collected on an Oxford X’Calibur S CCD 
diffractometer equipped with a graphite monochromator (MoKα radiation, λ= 
0.71073) and operated at room temperature. Data collection and refinement 
details are reported in the supplementary material. The structure was solved by 
direct methods and refined by full-matrix least-squares on F2 with SHELX978a 
program package.  
A calculated XRPD pattern was generated for Cu radiation using Mercury v 
1.4 and the atomic coordinates, space group and unit cell parameter from the 
single crystal data. 
MERCURY and SCHAKAL998b were used for the graphical representation of 
the results and PLATON8c was used for hydrogen bonding analysis. 
X-ray powder diffractograms were collectedon a Panalytical X’Pert Pro 
automated Diffractometer equipped with X’Celerator, CuKα, using glass 
sample holder. The tube voltage and amperage were set to 40 kV and 40 mA, 
respectively.The program used for data collection was set to record only the 
data points within the range 2θ= 3° - 40°. VT-XRPD analyses were performed 
equipping the diffractometer with an Anton Paar TTK 450 low-temperature 
camera that was a non-ambient attachment for powder X-ray diffraction 
studies in reflection geometry from -193 °C to +450 °C. 
2.2.10. FT-IR 
 
All FT-IR measurements were performed using Nicolet FT-IR 6700 Thermo 
Fischer equipped with ATR device. The analyses were performed on all 
samples and for each measurament 32 scans were recorded (See supplementary 
material). 
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2.2.11. Dissolution tests 
 
The calibration curve was constructed by plotting the absorbance against the 
concentration for four standard solutions of the sample in a sodium chloride 
solution 0.9% in standard concentrations. The analyses were performed using a 
dissolution tester and methods as described in the “European Pharmacopeia 
section 2.9.3 pg. 267”. The detector used was a UV-Vis Cary 50 Varian, 
equipped with an optic fiber. The program used was “Concentration” (Cary 50 
WinUV Software V.3) and the measurement for each standard was recorded at 
a fixed λ. The Kinetic solubilities were performed on a Hanson’s Vision 
Classic 6 dissolution tester coupled with a Varian Cary 50 UV-Vis 
Spectrophotometer. The program used was “Kinetic” (Cary 50 WinUV 
Software V.3), which recorded continuously the absorbance at fixed λ of a 
sodium chloride solution 0.9% (80mL) under stirring (250rpm) at 37°C in 
which were added approx. 10 mg of sample.The values obtained were 
converted from Abs/min into mol/min and for each sample two measurements 
were recorded. The thermodynamic solubilities were measured by leaving a 
sodium chloride solution 0.9%  of the sample under stirring at 500 rpm for 24 
h at 37°C. Then the suspensions were filtered, opportunly diluited and 
analyzed by UV-Vis Cary 50 Varian equipped with an optic fiber. The results 
were obtained using the calibration curves built in the first part of the 
experiment. For each sample two measurements were taken. Dissolution tests 
details are reported in the supplementary material. 
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2.3. Results and discussion 
 
The new salt, named ODV-OX Form A, was synthesized dissolving Des-
methyl-venlafaxine (synthesis taken from patent US2008,0015259A1) and 
oxalix acid in stoichiometric amount (1:1) in boiling water. The solution was 
filtered and left to evaporate at 60°C or at room temperature. 
ODV-OX Form A was subjected to a polymorph screening to identify the 
possible different crystal forms. It was recrystallized from different solvents by 
evaporation experiments in different conditions: at room temperature, at 4°C, 
at 60°C and at low pressure. Also slurry experiments were performed in 
different solvents. In addition to ODV-OX Form A (hydrate) other five 
different crystal forms (three hydrates and two anhydrous) were found: ODV-
OX Form C and Form D were obtained by evaporation experiments and ODV-
OX Form B, Form E and Form F were obtained by slurry experiments. 
The samples were characterized by different solid-state techniques: X-ray 
powder diffraction(XRPD), variable temperature XRPD (VT-XRPD), 
differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
evolved gas analysis (EGA), FT-IR and single crystal X-ray diffraction (SC-
XRD) for Form D (See supplementary material for details). The 
characterization was also implemented with stability tests at 40°C and 75%RH 
for one week. 
The SC-XRD analysis of ODV-OX Form D evidences the presence of four 
ODV cations, four oxalate anions and ten water molecules in the P-1 unit cell. 
As shown in figure 1, the amine group of the ODV cation forms hydrogen 
bonds with the oxalate anion that forms other three hydrogen bonds two of 
which with two water molecules and the other with another oxalate anion. 
Another molecule of water coordinates, through hydrogen bonds, the O-H 
groups of two ODV cation. The packing - Figure 1 - shows a structure that is 
characterized by chains of oxalate, molecules of water, and chains of ODV 
held together by hydrogen bonds. The chains of oxalate anions have a 
characteristic structure composed by dimers of oxalate anions held together by 
two molecules of water (Figure 1b) 
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(a) 
 
(b) 
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(c) 
 
Figure.1 (a) Hydrogen bonds of ODV cations and hydrogen oxalate anions in 
ODV-OX Form D through the coordination of water molecules; (b)Packing of 
oxalate anion in ODV-OX Form D;(c) Packing of ODV-OX Form D. 
 
In this case the correspondence of the structure, determined by SC-XRD, and 
that of bulk material was checked by comparing the calculated pattern with the 
experimental one (figure 2). 
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Figure.2 Comparison between XRD patterns of ODV-OX Form D 
experimental (red line) and calculated (blue line) by SC-XRD data. 
 
Differential scanning calorimetry (DSC) was used to measure the melting point 
of all compounds and to detect the presence of additional crystalline phases. 
Thermogravimetric analysis (TGA) was used to measure possible solvent loss. 
This tecnique was associated with evolved gas analysis (EGA) that measured 
IR spectra  and the kinetic profile of solvent loss during the TGA. 
In Table 1 the melting points obtained by DSC analyses, the weight loss 
obtained by TG analyses and the solvent identification by EG analyses are 
reported. The TGA results reported in the Table 1 evidence that four of the six 
different crystal forms found are hydrates and two (Form E and Form F) are 
anhydrous. The TGA profiles of Form E and Form F show only the 
degradation of sample after 200°C. The TGA profiles of Form A, Form B, 
Form C and Form D show weight loss before the degradation. In particular 
Form A and Form C show a very similar TGA profile with a weight loss of 
approx. 5% between 70-80°C that corresponds to approx. one molecule of 
water as evidenced by kinetic profile of water in EGA between 5 and 8 
minutes; after 100°C the TGA profile evidences the beginning of the 
degradation.  
The TGA profile of Form B shows a weight loss of 6.9% that in EGA 
correspondes to water loss. After 100°C the sample is stable and decomposes 
after 200°C as Form F.  
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The TGA profile of Form D shows a double loss of 6.02% and 5.5% that in 
EGA correspondes to water loss. All DSC and TGA profiles are showed in the 
supplementary material, while the kinetic profiles are showed in Figure 3. 
 
Table 1 Melting point (°C) and weight loss of six crystal form of ODV-OX.  
CRYSTAL 
FORMa 
DSC Onset (°C)  TGA LOSS 
(%)  
Solvent loss 
FORM A  79.5 5.6 water 
FORM B  76.4 6.9 water 
FORM C  79 4.7 water 
FORM D  78.1 6.02-5.5 water 
FORM E  128.7 - - 
FORM F - - - 
a Crystal form of ODV-OX salt. 
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Figure.3 Kinetic profiles of water loss of four hydrate forms of ODV-OX. 
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ODV-OX Form A, Form B, Form C and Form E were also analyzed by VT-
XRPD. Form A and Form C show the same behaviour (Figure 4 and 5): the 
samples were heated until 100°C and analyzed at 40°C and 80°C, the samples 
after 80°C begin to melt and at 100°C show the pattern of an amourphous 
phase.  
 
 
Figure.4 Comparison between XRPD patterns of ODV-OX Form A at RT and 
sample heated to 40°C, 80°C and 100°C. 
 
Figure.5 Comparison between XRPD patterns of ODV-OX Form C at RT and 
sample heated to 40°C, 80°C and 100°C. 
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Form B was heated until 160°C and measured from 60°C to 130°C every 10°C: 
the sample after 90°C converts into Form F but in the pattern there is a high 
amorphous content (Figure 6). After 120°C total conversion into amorphous 
phase is observed (Figure 7). 
 
 
Figure.6 Comparison between XRPD patterns of ODV-OX Form B at 100°C 
and ODV-OX Form F. 
 
Figure.7 Comparison between XRPD patterns of ODV-OX Form B at RT and 
sample heated to 40°C, 80°C, 100°C, 110°C, 120°C, 130°C and 160°C. 
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ODV-OX Form E was heated until 150°C and analyzed at different 
temperatures: the sample is stable until approx. 120°C and after this 
temperature converts into amorphous phase (Figure 8). 
 
 
Figure.8 Comparison between XRPD patterns of ODV-OX Form E at RT and 
sample heated to 40°C, 60°C, 100°C, 110°C, 120°C, 130°C and 150°C. 
 
The six crystal forms of ODV-OX were also subjected to stability test: the 
samples were stored for one week at 40°C and 75%RH and analyzed by 
XRPD.The Form A is stable (Figure 9); the Form B is stable for 3 days but 
after six days converts into Form A (Figure 10); the Form C is stable (Figure 
11);the Form D is stable (Figure 12); the Form E converts into Form A (Figure 
13) and the Form F converts into Form B (Figure 14). 
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Figure.9 Comparison between XRPD patterns of ODV-OX Form A and Form 
A stored for three and six days at 40°C and 75%RH. 
 
Figure.10 Comparison between XRPD patterns of ODV-OX Form B, Form B 
stored for three and six days at 40°C and 75%RH and Form A. 
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Figure.11 Comparison between XRPD patterns of ODV-OX Form C and Form 
C stored for three and six days at 40°C and 75%RH. 
 
Figure.12 Comparison between XRPD patterns of ODV-OX Form D and Form 
D stored for three and six days at 40°C and 75%RH. 
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Figure.13 Comparison between XRPD patterns of ODV-OX Form E, Form E 
stored for three and six days at 40°C and 75%RH and Form A. 
 
Figure.14 Comparison between XRPD patterns of ODV-OX Form F, Form F 
stored for three and six days at 40°C and 75%RH and Form B. 
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Dissolution tests were performed on ODV-OX and ODV-SUCC to compare 
the behavior of the oxalate and succinate salts of ODV.  
A particle size homogenization was performed on both salts (using stable 
forms) to obtaine reproducible results. The particle size analyses were 
performed using Beckman-Coulter LS100 Q particle size analyzer equipped 
with micro-volume cell. The samples were ground to obtain the same particles 
size distribution as shown in figure 15 and table 2. 
 
Table 2 Particle size results of ODV-OX and ODV-SUCC used for dissolution 
tests. 
Meana S.D.b Media
nc 
Moded D10e D50f D90g 
78.68  
µm 
47.48 
 µm 
77.56 
 µm 
116.3  
µm 
13.34 
 µm 
77.56 
 µm 
144.0  
µm 
a Mean: described the central location of the data; bS.D.: standard deviation 
described the spread; cMedian: numeric value separating the higher half of the 
distribution from the lower half; dMode: the value that occur most frequently in 
the distribution; eD10: the higher value of 10% of particles; f D50: the higher 
value of 50% of particles; gD90: the higher value of 90% of particles. 
 
Figure15 Particle size distribution of ODV-OX and ODV-SUCC used for 
dissolution tests. 
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The results of thermodynamic and kinetic solubilities, summarized in the table 
3, evidence an important increasing in solubility for the oxalate salt compared 
with the succinate salt. 
 
Table 3 Thermodynamic and kinetic solubility results of ODV oxalate and 
succinate salts. 
Salt Kinetic 
solubility 
Abs/min 
Thermodynamic 
solubility  
(g\L) 
PCL01_OX 1,31 142 
PCL01_SUCC 1,00 70 
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2.4. Conclusion 
 
In conclusion we have reported the preparation of a new salt of o-
Desmethylvenlafaxine (ODV): ODV oxalate (Form A) and other five different 
crystal forms (Form B, Form C, Form D, Form E and Form F). All samples 
obtained were characterized by a combination of different solid-state technique 
(XRPD, VT-XRPD, TGA, EGA, DSC, FT-IR). The ODV-OX Form D was 
also characterized by SC-XRD, this evidences the presence of water molecules 
in the structure. The TGA analyses evidence that four of the six different 
crystal forms found are hydrates and two (Form E and Foem F) are anhydrous. 
VT-XRPD analyses evidence that the monohydrate form A and C, after the 
water loss at 80-90°C, melt while Form B converts into anhydrous Form F that 
decomposes after 200°C as Form E. The stability tests performed at 40°C and 
75%RH show that Form A, C, and D are stable while B and E convert into 
Form A; Form F converts into Form B after six days. Comparative dissolution 
tests, performed after a particle size homogenization of ODV-OX and ODV-
SUCC, evidence a significant increasing in solubility for the oxalate salt (142 
g/L) compared with the succinate salt (70 g/L). 
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2.5. Supplementary Material 
 
-------------------------------------------------------------------------------------------- 
Legenda 
ODV = o-Desmethylvenlafaxine 
ODV-OX = o-Desmethylvenlafaxine oxalate salt 
ODV-SUCC = o-Desmethylvenlafaxine succinate salt 
------------------------------------------------------------------------------- 
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2.5.1. Crystal structure determination 
 
A colourless needle of ODV-OX form D having approximate dimensions of 0.2 x 
0.2 x 0.3 mm, was mounted on a glass fibre in random orientation. The	  sample	  
ODV-OX form D	   crystallises	   in	   a	   Triclinic	   system	   with	   cell	   parameter	   a	   =	  
9.4342(6) Å,	   b	   =	   13.0621(9)	   Å,	   c=	   18.0686(12)	   Å,	   α	   =	   109.701(6)	   deg.,	   β	   =	  
96.728(5)	  deg.,	  γ	  =	  99.120(5)	  deg.,	  V	  =	  2034.62	  Å3 with space group P-1. 
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Crystal data and details of measurements are summarized in Table 1.  
Table 1.Crystal data and details of measurement for ODV-OX FormD 
       Identification code                 odv_ox 
       Empirical formula                   C36 H64 N2 O17 
       Formula weight                      796.89 
       Temperature                         293(2) K 
       Wavelength                          0.71073 A 
       Crystal system, space group        Triclinic,  P-1 
       Unit cell dimensions          a = 9.4342(6) A      alpha = 109.701(6) deg. 
     b = 13.0621(9) A    beta = 96.728(5) deg. 
     c = 18.0686(12) A  gamma = 99.120(5) deg. 
      Volume                          2034.6(2) A^3 
       Z, Calculated density               2,  1.301 Mg/m^3 
       Absorption coefficient              0.103 mm^-1 
       F(000)                              860 
       Crystal size                        0.3 x 0.1 x 0.1 mm 
       Theta range for data collection    2.41 to 29.06 deg. 
       Limiting indices                    -12<=h<=11, -16<=k<=12, -24<=l<=23 
       Reflections collected / unique     18059 / 8206 [R(int) = 0.0847] 
     Completeness to theta =   25     89.5 % 
       Absorption correction               Semi-empirical from equivalents 
       Refinement method                   Full-matrix least-squares on F^2 
       Data / restraints / parameters     8206 / 0 / 561 
       Goodness-of-fit on F^2             1.023 
       Final R indices [I>2sigma(I)]      R1 = 0.1125, wR2 = 0.1320 
       R indices (all data)       R1 = 0.2874, wR2 = 0.1735 
       Extinction coefficient              0.0006(5) 
       Largest diff. peak and hole        0.322 and -0.218 e.A^-3 
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2.5.2. Thermal behaviour 
 
Differential	  scanning	  calorimetry	  measurements	  (DSC)	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Thermogravimetric	  analyses	  (TGA)	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2.5.3. XRPD Patterns 
ODV-­‐OX	  Form	  A	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
5,3111 3663,39 0,1624 16,63945 49,54 
9,5916 284,79 0,1299 9,22123 3,85 
10,5410 4098,59 0,1948 8,39270 55,43 
11,6532 578,34 0,1624 7,59410 7,82 
13,0162 232,42 0,1299 6,80176 3,14 
14,9010 705,17 0,1299 5,94540 9,54 
15,1949 1544,07 0,1299 5,83104 20,88 
15,8002 247,99 0,0974 5,60901 3,35 
16,1124 208,57 0,0974 5,50101 2,82 
16,5757 307,87 0,1299 5,34828 4,16 
17,2785 184,54 0,1624 5,13231 2,50 
17,8960 140,95 0,1624 4,95658 1,91 
18,9905 298,60 0,1299 4,67332 4,04 
19,8346 98,90 0,1948 4,47630 1,34 
Position [∞2Theta] (Copper (Cu))
10 20 30
Counts
0
400
1600
3600
6400
 PCL01_OX Form A
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21,1225 1312,00 0,2598 4,20618 17,74 
21,7703 231,60 0,2273 4,08247 3,13 
22,6391 222,85 0,1624 3,92773 3,01 
24,5723 407,75 0,1948 3,62292 5,51 
25,1012 624,92 0,1624 3,54777 8,45 
26,4739 7394,78 0,1948 3,36685 100,00 
27,5450 105,19 0,1948 3,23832 1,42 
28,4776 52,74 0,3897 3,13435 0,71 
30,1636 378,11 0,0974 2,96289 5,11 
31,8029 588,64 0,2598 2,81381 7,96 
33,4844 369,84 0,1624 2,67625 5,00 
34,1176 91,86 0,1948 2,62802 1,24 
36,3796 107,94 0,1299 2,46964 1,46 
 
  
97 
 
ODV-­‐OX	  Form	  B	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
5,3641 439,54 0,1948 16,47544 46,00 
7,2969 135,26 0,2598 12,11504 14,16 
8,5593 235,38 0,1624 10,33087 24,63 
9,2017 955,53 0,3247 9,61102 100,00 
10,6938 252,12 0,1948 8,27310 26,39 
11,2577 154,95 0,1948 7,85994 16,22 
11,8703 237,62 0,1948 7,45565 24,87 
12,8343 406,40 0,2273 6,89774 42,53 
13,8200 197,19 0,3897 6,40791 20,64 
14,6024 830,27 0,3572 6,06629 86,89 
15,5420 230,72 0,1299 5,70159 24,15 
16,6848 290,52 0,1948 5,31358 30,40 
17,1524 672,62 0,1948 5,16976 70,39 
18,1595 103,58 0,2598 4,88525 10,84 
18,9482 535,28 0,1624 4,68364 56,02 
Position [∞2Theta] (Copper (Cu))
10 20 30
Counts
0
100
400
900
 PCL01_OX Form B
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19,3943 748,29 0,1624 4,57690 78,31 
20,0165 515,51 0,1948 4,43603 53,95 
20,7798 79,22 0,1948 4,27478 8,29 
21,3128 279,49 0,1299 4,16905 29,25 
22,5201 341,19 0,1948 3,94820 35,71 
23,2400 131,11 0,3247 3,82751 13,72 
25,1180 195,56 0,1948 3,54544 20,47 
25,7557 140,77 0,3247 3,45908 14,73 
26,7095 401,99 0,2922 3,33769 42,07 
27,8737 143,24 0,3897 3,20087 14,99 
30,2597 232,08 0,2273 2,95370 24,29 
32,0673 48,88 0,3247 2,79121 5,12 
33,7123 41,46 0,3897 2,65868 4,34 
36,4194 90,82 0,2598 2,46703 9,51 
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ODV-­‐OX	  Form	  C	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
5,2961 5395,94 0,1624 16,68664 71,65 
9,7495 257,33 0,1299 9,07219 3,42 
10,5216 3929,64 0,0974 8,40814 52,18 
11,7391 1401,52 0,1299 7,53871 18,61 
13,1835 185,62 0,2598 6,71580 2,46 
14,4702 2021,75 0,1624 6,12142 26,85 
14,8339 1413,30 0,1299 5,97214 18,77 
15,4394 271,37 0,0974 5,73925 3,60 
15,7808 292,54 0,1299 5,61586 3,88 
16,4934 662,49 0,1299 5,37480 8,80 
16,8009 1497,51 0,1624 5,27710 19,89 
18,1278 241,99 0,1299 4,89371 3,21 
18,3851 176,62 0,0974 4,82581 2,35 
18,8151 575,49 0,0974 4,71647 7,64 
19,4207 1157,52 0,1299 4,57076 15,37 
20,6912 131,82 0,1624 4,29287 1,75 
21,0662 1232,22 0,1299 4,21730 16,36 
Position [∞2Theta] (Copper (Cu))
10 20 30
Counts
0
400
1600
3600
6400
 PCL01-OX Form C
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21,2402 1024,60 0,1299 4,18315 13,61 
21,8165 234,32 0,2598 4,07393 3,11 
22,2994 330,73 0,1624 3,98679 4,39 
23,1901 309,29 0,1299 3,83564 4,11 
23,4853 483,46 0,0974 3,78809 6,42 
23,6727 531,97 0,1299 3,75853 7,06 
24,5807 551,81 0,2273 3,62171 7,33 
25,5582 209,83 0,1948 3,48537 2,79 
26,4006 6691,82 0,1299 3,37603 88,86 
26,5784 7530,57 0,0974 3,35386 100,00 
29,6022 114,36 0,3897 3,01779 1,52 
30,1896 214,77 0,1624 2,96039 2,85 
31,9491 608,43 0,2598 2,80127 8,08 
33,4328 104,64 0,3247 2,68027 1,39 
34,2782 109,57 0,2598 2,61608 1,46 
36,7878 34,86 0,7793 2,44317 0,46 
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ODV-­‐OX	  Form	  D	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
5,9933 6784,10 0,1004 14,74705 100,00 
7,4510 169,33 0,1673 11,86492 2,50 
8,6396 212,16 0,1673 10,23503 3,13 
9,3377 442,55 0,1673 9,47136 6,52 
10,1712 591,61 0,1171 8,69703 8,72 
10,9667 1377,86 0,1506 8,06785 20,31 
11,3202 165,51 0,1338 7,81672 2,44 
11,9003 3456,27 0,1171 7,43691 50,95 
12,7210 262,10 0,1004 6,95893 3,86 
13,0787 194,35 0,1673 6,76938 2,86 
13,5527 62,73 0,1004 6,53370 0,92 
14,2075 1560,88 0,1171 6,23399 23,01 
14,5834 2237,03 0,1171 6,07414 32,97 
14,7491 1971,58 0,1338 6,00629 29,06 
Position [∞2Theta] (Cobalt (Co))
10 20 30 40
Counts
0
2500
10000
 pcl01_ox_lt_b in P-1
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15,3062 894,50 0,1673 5,78889 13,19 
16,0182 712,46 0,1338 5,53316 10,50 
16,3323 218,31 0,1506 5,42745 3,22 
16,7051 1036,25 0,1506 5,30714 15,27 
17,0828 317,43 0,1338 5,19065 4,68 
17,6891 1152,99 0,0669 5,01407 17,00 
17,9040 1312,50 0,1004 4,95439 19,35 
18,5494 647,40 0,1338 4,78343 9,54 
18,9965 971,29 0,1506 4,67186 14,32 
19,3387 438,84 0,1506 4,58994 6,47 
19,7187 351,89 0,0836 4,50234 5,19 
20,3497 2124,19 0,1673 4,36413 31,31 
20,9279 1339,29 0,1506 4,24485 19,74 
21,4155 492,44 0,1338 4,14930 7,26 
22,2480 551,18 0,1338 3,99588 8,12 
22,6262 739,99 0,1020 3,92668 10,91 
22,7293 694,54 0,0836 3,91234 10,24 
23,1464 356,05 0,1004 3,84278 5,25 
23,9739 373,17 0,1673 3,71198 5,50 
24,7683 174,87 0,1171 3,59470 2,58 
25,1096 89,64 0,1338 3,54661 1,32 
25,6735 693,97 0,0836 3,46997 10,23 
26,0899 212,99 0,1171 3,41553 3,14 
26,5592 88,29 0,1004 3,35624 1,30 
26,9487 781,15 0,1338 3,30860 11,51 
27,5352 579,29 0,1004 3,23945 8,54 
28,9533 246,66 0,1673 3,08393 3,64 
30,1383 130,98 0,1004 2,96532 1,93 
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30,4877 100,47 0,1004 2,93212 1,48 
30,8740 142,32 0,1673 2,89631 2,10 
31,5166 274,34 0,1673 2,83871 4,04 
32,8228 177,42 0,1004 2,72867 2,62 
33,4907 56,98 0,3346 2,67576 0,84 
33,9368 26,85 0,1338 2,64160 0,40 
34,4310 102,31 0,2676 2,60481 1,51 
35,4317 304,16 0,2007 2,53351 4,48 
36,1596 87,17 0,1673 2,48416 1,28 
36,5026 122,10 0,1338 2,46160 1,80 
37,2102 98,14 0,1673 2,41640 1,45 
37,9115 124,71 0,1338 2,37330 1,84 
38,6464 46,04 0,1673 2,32984 0,68 
39,1466 61,80 0,2007 2,30122 0,91 
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ODV-­‐OX	  Form	  E	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
5,9933 6784,10 0,1004 14,74705 100,00 
7,4510 169,33 0,1673 11,86492 2,50 
8,6396 212,16 0,1673 10,23503 3,13 
9,3377 442,55 0,1673 9,47136 6,52 
10,1712 591,61 0,1171 8,69703 8,72 
10,9667 1377,86 0,1506 8,06785 20,31 
11,3202 165,51 0,1338 7,81672 2,44 
11,9003 3456,27 0,1171 7,43691 50,95 
12,7210 262,10 0,1004 6,95893 3,86 
13,0787 194,35 0,1673 6,76938 2,86 
13,5527 62,73 0,1004 6,53370 0,92 
14,2075 1560,88 0,1171 6,23399 23,01 
14,5834 2237,03 0,1171 6,07414 32,97 
14,7491 1971,58 0,1338 6,00629 29,06 
15,3062 894,50 0,1673 5,78889 13,19 
Position [∞2Theta] (Copper (Cu))
10 20 30
Counts
0
400
1600
3600
6400
 PCL01-OX-SL-ACT-100C
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16,0182 712,46 0,1338 5,53316 10,50 
16,3323 218,31 0,1506 5,42745 3,22 
16,7051 1036,25 0,1506 5,30714 15,27 
17,0828 317,43 0,1338 5,19065 4,68 
17,6891 1152,99 0,0669 5,01407 17,00 
17,9040 1312,50 0,1004 4,95439 19,35 
18,5494 647,40 0,1338 4,78343 9,54 
18,9965 971,29 0,1506 4,67186 14,32 
19,3387 438,84 0,1506 4,58994 6,47 
19,7187 351,89 0,0836 4,50234 5,19 
20,3497 2124,19 0,1673 4,36413 31,31 
20,9279 1339,29 0,1506 4,24485 19,74 
21,4155 492,44 0,1338 4,14930 7,26 
22,2480 551,18 0,1338 3,99588 8,12 
22,6262 739,99 0,1020 3,92668 10,91 
22,7293 694,54 0,0836 3,91234 10,24 
23,1464 356,05 0,1004 3,84278 5,25 
23,9739 373,17 0,1673 3,71198 5,50 
24,7683 174,87 0,1171 3,59470 2,58 
25,1096 89,64 0,1338 3,54661 1,32 
25,6735 693,97 0,0836 3,46997 10,23 
26,0899 212,99 0,1171 3,41553 3,14 
26,5592 88,29 0,1004 3,35624 1,30 
26,9487 781,15 0,1338 3,30860 11,51 
27,5352 579,29 0,1004 3,23945 8,54 
28,9533 246,66 0,1673 3,08393 3,64 
30,1383 130,98 0,1004 2,96532 1,93 
30,4877 100,47 0,1004 2,93212 1,48 
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30,8740 142,32 0,1673 2,89631 2,10 
31,5166 274,34 0,1673 2,83871 4,04 
32,8228 177,42 0,1004 2,72867 2,62 
33,4907 56,98 0,3346 2,67576 0,84 
33,9368 26,85 0,1338 2,64160 0,40 
34,4310 102,31 0,2676 2,60481 1,51 
35,4317 304,16 0,2007 2,53351 4,48 
36,1596 87,17 0,1673 2,48416 1,28 
36,5026 122,10 0,1338 2,46160 1,80 
37,2102 98,14 0,1673 2,41640 1,45 
37,9115 124,71 0,1338 2,37330 1,84 
38,6464 46,04 0,1673 2,32984 0,68 
39,1466 61,80 0,2007 2,30122 0,91 
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ODV-­‐OX	  Form	  F	  
 
Pos. [°2Th.] Height [cts] FWHM [°2Th.] d-spacing [Å] Rel. Int. [%] 
7,3730 1487,16 0,0836 11,99026 34,31 
7,7215 683,63 0,1004 11,44988 15,77 
8,5137 1788,29 0,1004 10,38606 41,25 
9,2071 4334,96 0,1506 9,60537 100,00 
10,0299 869,76 0,1171 8,81923 20,06 
11,2693 2030,73 0,1171 7,85193 46,85 
13,0015 2148,97 0,1171 6,80945 49,57 
13,4206 1077,84 0,0836 6,59770 24,86 
13,9285 877,75 0,1171 6,35825 20,25 
14,7714 2934,99 0,1338 5,99727 67,71 
15,4872 261,62 0,0836 5,72165 6,04 
15,9626 530,52 0,1004 5,55232 12,24 
16,2689 607,35 0,1004 5,44844 14,01 
16,8915 913,00 0,0836 5,24901 21,06 
Position [∞2Theta] (Copper (Cu))
10 20 30
Counts
0
400
1600
3600
 DEP001 Form B
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17,0574 1738,08 0,0836 5,19831 40,09 
17,2375 778,37 0,0836 5,14443 17,96 
17,5584 405,20 0,1171 5,05113 9,35 
18,2456 201,61 0,1004 4,86238 4,65 
19,1534 2439,25 0,1673 4,63394 56,27 
19,7009 766,51 0,1338 4,50637 17,68 
20,0695 941,88 0,1171 4,42442 21,73 
20,3571 421,26 0,1004 4,36258 9,72 
21,1667 678,77 0,1171 4,19751 15,66 
21,8812 150,84 0,1338 4,06203 3,48 
22,5182 1756,74 0,0836 3,94854 40,52 
22,6324 1761,69 0,1004 3,92887 40,64 
23,4101 320,55 0,0836 3,80008 7,39 
23,8629 506,82 0,1004 3,72900 11,69 
24,7699 95,01 0,1338 3,59447 2,19 
25,4173 359,74 0,0669 3,50436 8,30 
25,7212 513,99 0,1171 3,46365 11,86 
26,4636 103,87 0,2676 3,36814 2,40 
27,4076 165,78 0,1338 3,25423 3,82 
28,0269 742,23 0,1171 3,18372 17,12 
29,1487 81,52 0,1338 3,06369 1,88 
30,0743 1197,37 0,1338 2,97148 27,62 
30,4956 84,06 0,1004 2,93138 1,94 
31,4234 155,81 0,2007 2,84691 3,59 
32,6729 76,16 0,1004 2,74084 1,76 
33,4049 153,79 0,1338 2,68244 3,55 
34,9156 168,20 0,2007 2,56976 3,88 
35,3807 77,24 0,3346 2,53704 1,78 
109 
 
36,2696 236,59 0,1673 2,47688 5,46 
36,7741 195,12 0,1338 2,44405 4,50 
39,7162 70,96 0,1004 2,26952 1,64 
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2.5.4. FT-IR 
ODV-­‐OX	  Form	  A	  
 
 
 
 
 
 
 
ODV-­‐OX	  Form	  B	  
 
 
 
 
 
 
ODV-­‐OX	  Form	  F	  
 
 
 
 
 
 
111 
 
ODV-­‐OX	  Form	  C	  
 
 
 
 
 
 
	  
ODV-­‐OX	  Form	  D	  
 
 
 
 
 
 
 
ODV-­‐OX	  Form	  E	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2.5.5. Dissolution tests 
Calibration	  curve	  	  
The calibration curves were built using four solutions at different concentration for each salt: 
 
 1.    1.5*10-4 mol/L 
 2.    7.5*10-5 mol/L 
 3.    5.0*10-5 mol/L 
 4.    3.5*10-5 mol/L 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 275.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      5                                                                                 
Standard/Sample averaging  OFF                                                                               
Method Weight                 1.0000                                                                            
Weight units                    g                                                                                 
Method Volume               1.000                                                                             
Volume units                 mL                                                                                
Factor = (Method Wt * Sample Vol)/(Sample Wt * Method Vol)                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
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Calibration	  of	  ODV_OX	  (Form	  A)	  
 
Calibration eqn                Abs = 1002.4 * Conc 
Correlation Coefficient        0.99189  
Calibration time               21/05/2008 10.40.56                                                                              
 Calibration	  of	  ODV_SUCC	  (Form	  B)	  
 
 
 
Calibration eqn                 Abs = 1141.4 * Conc 
Correlation Coefficient        0.99638 
Calibration time                21/05/2008 10.50.36                                                                               
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3. CHARACTERIZATION OF NEW FOUR ORGANIC SALTS OF 
LIDOCAINE 
3.1. Introduction 
 
Lidocaine (2-diethylamino-N-(2,6-dimethylphenyl)acetamide) is the first amide-
type anesthetic synthetized by Nils Löfgren in 1943.1 
Lidocaine (Scheme 1) is a typical local anesthetic, also known for its treatment in 
the ventricular tachycardia (a cardiac arhythmia) as an intravenous injection 
solution (See e.g. U.S. Patent N0. 3,968,205).  
CH3
CH3
NH
O
N CH3
CH3
CH3
CH3
NH
O
N
+
CH3
CH3
H
Lidocaine (1) Lidocaine cation (1H)  
Scheme 1. 
 
Lidocaine is also widely used as a vasoconstrictor to reduce regional blood flow 
in topical applications or aerosols (such as nasal aerosols to reduce nasal 
congestion). (See U.S. Pat. No. 5,534,242). In addition, lidocaine is known for its 
therapeutic effects in reducing post-herpetic neuralgia (PHN), nerve injury pain 
from shingles (herpes zoster and post herpetic neuralgia) and analogous 
neuropathies. For example, U.S. Pat. No. RE37,727 discloses methods employing 
lidocaine intradermal administration by transport of lidocaine from the skin 
surface, using patches and dressings, into the skin2. 
Lidocaine is present in the European Pharmacopoeia in two forms: the free base, 
not very stable and characterized by a very low solubility in aqueous solution and 
the hydrochloride salt, characterized by a very high solubility in aqueous solution 
and used generally for the preparation of injection solutions. 
To improve solubility, stability and therefore efficacy of the free base,  
lidocaine is usually made available as salts. In the literature different examples are 
reported of lidocaine salts with organic acids to improve the properties of the free 
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base and with other active ingredients to combine different therapeutic effects in 
the same drug.3 
Lidocaine is labeled as 1 (Scheme 1) in the neutral form and 1H in the cationic 
form. 
In this study, four salts of 1 with oxalic, fumaric, malonic and succinic acid were 
prepared using conventional solution chemistry and using mechanochemical 
methods by mechanical mixing of the reactants (grinding or kneading).4 
The powders obtained were characterized by X-ray powder diffraction (XRPD), 
differential scanning calorimetry (DSC), FT-IR and solid-state NMR (SS NMR). 
The lidocaine oxalate, fumarate and malonate were also characterized by single 
crystal X-ray diffraction (SC-XRD). The structure of lidocaine succinate was 
determined by X-ray powder diffraction. In addition to the synthesis and solid-
state characterization, the salts were also subjected to dissolution tests in aqueous 
solution and the results obtained were compared with thermodynamic and kinetic 
solubility of lidocaine freebase and lidocaine hydrochloride salt.  
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3.2. Experimental section 
 
All reactants were purchased from Aldrich and used without further purification. 
Reagent grade solvents and doubly distilled water were used. For dissolution tests 
a 0.9%. sodium chloride solution was used. 
3.2.1. Solution synthesis 
 
All salts were crystallized by room temperature evaporation of a solution obtained 
dissolving a stoichiometric mixture (1-1) of lidocaine and organic acid in hot 
methanol 99.8%. The amount of reagent was chosen so that 200-300 mg of solid 
product could be obtained (see table 1). 
3.2.2. Mechanochemistry 
 
All salts were quantitatively obtained as polycrystalline materials by grinding or 
kneading of lidocaine and organic acid in a 1:1 ratio. The experiments were 
performed with a Retsch MM 200 grinder for 15 minutes at a frequency of 30Hz. 
 
Salts Lidocaine/mg Acid/mg 
1H oxalate 200 76.8 
1H fumarate 200 99.6 
1H succinate 200 100.7 
1H malonate 200 88.8 
Table1. 
 
3.2.3. Thermal measurements 
 
Thermogravimetric analyses were performed using a simultaneus STA 409 PC 
Luxx® Netzsch equipped with a thermocouple for the direct measurament of DSC 
signal, and a thermobalance for the measurement of the TGA signal. The samples 
(5-15 mg) were placed in aluminium pierced pans, and the heating was carried out 
at 10°C min–1 in N2 atmosphere. 
Calorimetric measurements were performed  using a DSC 200 F3 Maia® 
differential scanning calorimeter equipped with an intra-cooler. The samples (2–4 
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mg) were placed in aluminium pierced pans, and the heating was carried out at 
10°C min–1 in N2 atmosphere.(See supplementary material) 
 
3.2.4. Single crystal X-Ray diffraction 
 
Single-crystal data were collected on an Oxford X’Calibur S CCD diffractometer 
equipped with a graphite monochromator (MoKα radiation, λ = 0.71073) and 
operated at room temperature. The structure was solved by direct methods and 
refined by full-matrix least-squares on F2 with SHELX975a program package.  
A calculated XRPD pattern was generated for Cu radiation using Mercury v 1.4 
and the atomic coordinates, space group, and unit cell parameters from the single 
crystal data. 
MERCURY and SCHAKAL995b were used for the graphical representation of the 
results and PLATON5c was used for hydrogen bonding analysis. 
3.2.5. Powder  X-Ray diffraction 
 
Diffraction patterns from 3° to 40° in 2θ were collected on a PANalytical 
diffractometer with Bragg–Brentano geometry (Cu Kα radiation, detector: 
X'celerator, step size Δ2θ = 0.0167°, counting time per step = 20 s), using a glass 
sample holder. The tube voltage and amperage were set to 40 kV and 40 mA, 
respectively. 
For the structure solution from X-ray powder diffraction of 1H succinate crystal 
phase, diffraction pattern was collected from 5 to 70° in 2θ with a step size of 
0.00835° and counting time per step = 50 s. The structure was solved by analogy 
with the structure of 1H fumarate phase, and refined by Rietveld analysis. 
Rietveld refinement was performed with software GSAS.6 
A Cosine Fourier series with 10 coefficients and a Pseudo-Voigt function (type 3) 
were used to fit respectively background and peak shape. A spherical harmonics 
model was used to describe preferred orientation. Soft constraints were applied on 
bond distances and angles of both molecules. An overall thermal parameter for 
each atom species was adopted. Refinement converged with χ2 = 11.04, Rwp = 
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10.84 RF2= 8.96. Figure 1 shows experimental, calculated and difference curves. 
 
Figure 1. Experimental (red crosses), calculated (green) and difference (purple) curves of 
1H succinate phase. 
3.2.6. FT-IR 
 
All FT-IR measurements were performed using Nicolet FT-IR 6700 Thermo 
Fischer equipped with ATR device. The analyses were performed on all samples 
and for each measurement 32 scans were recorded (See supplemetary material). 
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3.2.7. Solid-state Nuclear Magnetic Resonance (SS NMR) spectroscopy 
 
SS NMR experiments were recorded on a Bruker Avance II 400 instrument. The 
spactra were collected and interpreted by the Research Group of Prof. Roberto 
Gobetto at the University of Torino. 
3.2.8. Dissolution tests 
The calibration curve was built by plotting the absorbance against  concentrations 
for four standard solutions of the sample in a sodium chloride solution 0.9% in 
standard concentrations. The analyses were performed using a dissolution tester 
and methods as described in the “European Pharmacopeia section 2.9.3 pg. 267”. 
The detector used was a UV-Vis Cary 50 Varian, equipped with an optic fiber. 
The program used was “Concentration” (Cary 50 WinUV Software V.3) and the 
measurement for each standard was recorded at a fixed λ. The Kinetic solubilities 
were performed on a Hanson’s Vision Classic 6 dissolution tester coupled with a 
Varian Cary 50 UV-Vis Spectrophotometer. The program used was “Kinetic” 
(Cary 50 WinUV Software V.3), which recorded continuously the absorbance at 
fixed λ of a sodium chloride solution 0.9% (80mL) under stirring (250 rpm) at 
37°C in which were added approx. 10mg of sample. The values obtained were 
converted from Abs/min into mol/min and for each sample two measurements 
were recorded. The thermodynamic solubilities were measured by leaving a 
sodium chloride solution 0.9% of the sample under stirring at 500 rpm for 24 h at 
37°C. Then the suspensions were filtered, opportunly diluited and analyzed by 
UV-Vis Cary 50 Varian equipped with an optic fiber. The results were obtained 
using the calibration curves built in the first part of the experiment. For each 
sample two measurements were taken. Dissolution tests details are reported in the 
supplementary material. 
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3.3. Results and discussion 
 
In this work four salts of lidocaine were synthesized with carboxylic acids: 
lidocaine oxalate (1H·oxalate), lidocaine fumarate (1H·fumarate), lidocaine 
malonate (1H·malonate) and lidocaine succinate (1H·succinate). All salts, 
crystallized by evaporation at room temperature from methanol solution and by 
grinding or kneading, were investigated with solid state techniques such as X-ray 
powder diffraction - to determine the diffraction pattern, differential scanning 
calorimetry - to determine the melting point, FT-IR and SS NMR for a 
characterization of molecular adducts.  
The 1H oxalate, fumarate and malonate were also characterized by SC-XRD. In 
these three cases the correspondences, between the structures determined by SC-
XRD and those of bulk materials, were checked by comparing calculated and 
measured patterns (See supplementary material).  
In the structure of 1H fumarate (Figure 2) intermolecular hydrogen bonds are 
observed. The carboxylate group of the hydrogen fumarate anion forms hydrogen 
bonds with two molecules of 1H, one of which with the amide group (N1-H1) and 
the other with the amino group (N2). The carboxylic group (O100) of the 
hydrogen fumarate anion forms an hydrogen bond with the carboxylate group 
(O300) of another anion molecule resulting in chains (Figure 3). 
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Figure 2. The hydrogen bonds of 1H fumarate salt. 
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Figure 3. The packing of 1H fumarate salt. 
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In the structure of 1H malonate (Figure 4), the malonate forms one intramolecular 
(O2···O3) and two intermolecular hydrogen bonds with two molecules of 1H, one 
of which with the amide group (N1-H100) and the other with the amino group 
(N2) (Figure 5). 
 
Figure 4. The hydrogen bonds of 1H malonate salt. 
 
Figure 5. The packing of 1H malonate salt. 
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The structure of 1H oxalate (Figure 6) evidences also the presence of 
intermolecular hydrogen bonds. There are two hydrogen bonds between the 
oxalate molecules, which form dimers, and two hydrogen bonds of carboxylate 
group of hydrogen oxalate anion with two molecules of 1H one of which with the 
amide group (N1-H) and the other with the amino group (N2). The dimer, formed 
by two oxalte molecules and involved between molecules of 1H, is the motif 
repeated into the chains which characterizes the structure of the crystal (Figure 7). 
 
 
Figure 6. The hydrogen bonds of 1H oxalate salt. 
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Figure 7. The packing of 1H oxalate salt. 
 
The structure of 1H succinate was determined by X-ray powder diffraction, using 
also the analogy with the structure of 1H fumarate phase, and was refined by 
Rietveld analysis. 
In the structure of 1H succinate (Figure 8) the carboxylate group forms hydrogen 
bonds with two molecules of 1H, one of which with the amide group (N10) of one 
molecule of 1H and the other with the amino group (N5). Furthermore, the 
carboxylic group (O20) of the succinate anion forms an hydrogen bond with the 
carboxylate group (O2) of another anion molecule (Figure 9). 
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Figure 8. The hydrogen bonds of 1H succinate salt. 
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Figure 9. The packing of 1H succinate salt.
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Crystal data and details of measurements for compounds 1H oxalate, 1H 
fumarate, 1H succinate and 1H malonate are summarized in table 2. 
 
compound 1H oxalate 1H fumarate 1H malonate 1H succinate 
Formula C16H24N2O5 C18H26N2O5 C17H23N2O5 C18N2O5 
Mr 324.37 350.41 336.38 324.21 
system Monoclinic Orthorombic Monoclinic Orthorombic 
space group P21/c P 212121 P21/c P 212121 
a [Å] 10.5817(8) 10.442(5)  12.317(4) 10.4949(3) 
b [Å] 10.3447(5) 16.273(5)  10.503(3) 10.8924(3) 
c [Å] 15.3496(1) 24.3454(1) 15.283(4) 16.581(4) 
α  [°] 90.00 90.00 90.00 90.00 
β  [°] 102.719(7) 90.00 109.67 90.00 
γ[°] 90.00 90.00 90.00 90.00 
V [Å³] 1639.01(18) 1862.7(14) 1861.6(9) 1895.4(6) 
Z 4 4 4 4 
dcalc 1.315 1.250 1.200 - 
F(000) 696 752 720 - 
measured reflns 7219 5838 8906 - 
unique reflns 3744 3974 4228 - 
refined 
parameters 
226 234 226 - 
GOF on F² 1.032 1.029 1.013 - 
R1 [on F, I>2σ(I)] 0.0784 0.0899 0.0766 - 
wR2(onF²,all data) 0.2002 0.2174 0.1992 - 
Table 2. Crystal data of 1H salts. 
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The SS NMR technique has been used for the definition of the crystal nature, 
whether molecular or salts, resulting from the positioning of the acid protons 
along the O···H···N interactions. Indeed, it is well-known that the 13C chemical 
shift of the carboxylic carbon atom represents a good indicator of the protonation 
state of the COOH group7a-c. Furthermore, 15N NMR studies on hydrogen-bonded 
systems have shown that nitrogen protonation or formation of hydrogen bonds 
results in high- or low-frequency shifts of the nitrogen signal, according to the 
type of nitrogen atom and to the nature of the interaction.7d–f, 8 
The analysis of the 13C resonances around 160-179 ppm and of the 15N signal 
around 14-29 ppm allowed to ascertain the transfer of a single proton from the 
acid to the lidocaine with formation of one carboxylate and one ammonium group. 
Thus all adducts can be described as salts (See supplemenatary material). 
Differential scanning calorimetry was used to measure the melting point of all 
compounds and to detect the presence of additional crystalline phases.  
To improve their characterization, the salts were also subjected to dissolution tests 
in aqueous solution and the results obtained are compared with thermodynamic 
and kinetic solubility of lidocaine free base and lidocaine hydrochloride salt. 
In Table 3 the melting points and dissolution results of four carboxylic salts, 
hydrochloride salt and lidocaine free base are reported.  
The results show an increasing of the melting point from free base to lidocaine 
carboxylic salts, in fact, lidocaine free base and hydrochloride salt show a melting 
point between 60°C and 70°C, while the salts synthesized show a melting point 
higher than 100°C. 
The malonate salt was also reported in a work of 1994 with other salts of 
lidocaine (maleate, adipate and tosylate). These salts were characterized using 
1HNMR, IR, MS, UV-Vis. Melting point, tests of skin permeability and apparent 
partition coefficients were also carried out. The melting points of these salts, as 
those of samples characterized in this work, have higher melting point than 
lidocaine and lidocaine hydrochloride.3e 
The dissolution rates of lidocaine free base and fumarate salt are lower than 
succinate, oxalate and malonate salts, on the other hand these last three salts show 
a good thermodynamic solubility more than 120 g/L.  
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The best value of dissolution rate is showed by the hydrochloride salt, it also has 
the higher thermodynamic solubility.  
The results of kinetic solubilities are reported in Figure 10, this graphic shows a 
comparison between the dissolution curves (ABS/min) obtained. 
 
Sample  MP(°C)  Thermodynamic 
Solubility(g\L)  
Kinetic 
Solubility(mol\min)  
1H  67.5  3.13  2.13*10-5 
1H chlorhydrate  75.8  >633  1.85*10-3 
1H succinate 113.5  >321 1.5*10-4 
1H malonate 140.2  >279 1.5*10-4 
1H oxalate 159.2  128.5 1.05*10-4 
1H fumarate 186.9  71 7.31*10-5 
Table 3. 
 
Figure 10: Kinetic profile. 
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3.4. Conclusion 
 
In this study four lidocaine salts of dicarboxylic acids (oxalate, fumarate, 
malonate and succinate) were synthesized and characterized by different solid 
state techniques. SS NMR characterization allowed the distinction between salts 
or co-crystals obtained: in all compounds a proton-transfer was identified both in 
solid-state reaction and syntheses solvent assisted. The oxalate, fumarate and 
malonate salts were also characterized by single crystal XRD while the structure 
of succinate salt was obtained by powder resolution. All salts show an 
improvement of chemical-physic stability, in fact, there is an important increasing 
of the melting points respect to free base and hydrochloride salt. Furthermore, the 
dissolution tests of the salts obtained show a higher solubility in water in 
comparison with free base, while, these are lower than hydrochloride salt 
solubility. The solubility of an API, in fact, is a very important step for its 
development because before undergoing pharmacological evaluation and other 
preclinical studies, synthetic or natural active principles must usually be 
dissolved. However, one must keep in mind that making a drug molecule more 
water-soluble can also be a drawback. There is a general tendency that the more 
water-soluble a compound is, the more diffusible it is. This causes it to be less 
specific in its activity, and more liable to rapid elimination and, therefore, shorter 
acting.9 
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3.5. Supplementary Material 
 
------------------------------------------------------------------------------- 
Legenda 
1 = Lidocaine 
1H oxalate= Lidocaine oxalate 
1H fumarate= Lidocaine fumarate 
1H malonate= Lidocaine malonate 
1H succinate = Lidocaine succinate 
1H chlorhydrate = Lidocaine hydrochloride  
------------------------------------------------------------------------------- 	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3.5.1. Thermal measuraments 
 
 
 
 
1H 
1H chlorohydrate 
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1H oxalate 
1H fumarate 
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1H succinate 
1H malonate 
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3.5.2. XRPD Patterns 
 
Comparison between diffraction patterns recorded on products obtained 
crystallization (red line) and diffraction patterns computed on the basis of the 
structures resolution (black line). 
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3.5.3. FT-IR 
 
1H	  oxalate	  
 
 
1H	  fumarate	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3.5.4. Dissolution tests 
Calibration	  curve	  1	  
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard             Concentration    F  Readings  
                            (mol/L)                   
________________________________________________ 
Std 1                     0.000643          0.2362  
Std 2                     0.001285          0.5010  
Std 3                     0.001928         0.8004  
Std 4                     0.002570         1.0789  
 
Calibration eqn                 Abs = 440.15668*Conc -0.05299                                                     
Correlation Coefficient         0.99951                                                                           
Calibration time                27/10/2010 11.49.16                                                   
 	  
142 
 
Calibration	  curve	  1H	  hydrochloride	  
 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard             Concentration    F  Readings  
                            (mol/L)                   
________________________________________________ 
Std 1                     0.000446          0.2132  
Std 2                     0.000892          0.4362  
Std 3                     0.001339          0.6217  
Std 4                     0.001785          0.8118  
 
Calibration eqn                 Abs = 443.85272*Conc +0.02560                                                     
Correlation Coefficient         0.99816                                                                           
Calibration time                27/10/2010 12.09.08                                                               
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Calibration	  curve	  1H	  oxalate	  
 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard          Concentration     F  Readings  
                         (mol/L)                   
________________________________________________ 
Std 1                     0.000327         0.1187  
Std 2                     0.000655         0.2830  
Std 3                     0.000983         0.4609  
Std 4                     0.001310         0.6054  
 
Calibration eqn                 Abs = 499.89432*Conc -0.04229                                                     
Correlation Coefficient         0.99851                                                                           
Calibration time                27/10/2010 11.55.37                                                               
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Calibration	  curve	  1H	  fumarate	  
 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard          Concentration      F  Readings  
                         (mol/L)                   
________________________________________________ 
Std 1                     0.000176         0.2246  
Std 2                     0.000351         0.4372  
Std 3                     0.000527         0.6428  
Std 4                     0.000703         0.8829  
 
 
Calibration eqn                 Abs = 1241*Conc +0.00174                                                          
Correlation Coefficient         0.99889                                                                           
Calibration time                27/10/2010 12.03.12                                                               
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Calibration	  curve	  1H	  malonate	  
 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard          Concentration     F  Readings  
                         (mol/L)                   
________________________________________________ 
Std 1                     0.000369         0.1582  
Std 2                     0.000738         0.3298  
Std 3                     0.001106         0.4710  
Std 4                     0.001475         0.6439  
 
 
Calibration eqn                 Abs = 433.63333*Conc +0.00090                                                     
Correlation Coefficient         0.99853                                                                           
Calibration time                27/10/2010 12.20.45                                                               
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Calibration	  curve	  1H	  succinate	  
 
Instrument Settings 
Instrument                      Cary 50                                                                           
Instrument version no.          3.00                                                                              
Wavelength (nm)                 265.0                                                                             
Ordinate Mode                   Abs                                                                               
Ave Time (sec)                  0.1000                                                                           
Replicates                      1                                                                                 
Standard/Sample averaging  OFF                                                                               
Fit type                       Linear                                                                            
Min R²                          0.95000                                                                           
Concentration units             mol/L                                                                             
Calibration 
Standard           Concentration     F  Readings  
                         (mol/L )                  
________________________________________________ 
Std 1                     0.000425         0.1835  
Std 2                     0.000850         0.3693  
Std 3                     0.001275         0.5608  
Std 4                     0.001700         0.7427  
 
Calibration eqn                 Abs = 439.80038*Conc -0.00323                                                     
Correlation Coefficient         0.99991                                                                           
Calibration time                27/10/2010 12.15.34       
                                                         
147 
 
3.5.5. Solid state NMR 
 
The spectra were collected and interpretated by the Research Group of Prof. 
Roberto Gobetto at the University of Torino. 
All 13C spectra (Figure 1) are characterized by a signal at high frequencies (166-
169 ppm) typical of carboxylate carbon atom together with a peak around 162-166 
ppm attributed to the COOH group. In the 15N CPMAS spectra (Figure 2) the 
amplitude of the N12 signal shift (from 15-17 ppm to about 25-29 ppm) indicates 
the complete protonation of the nitrogen atom in agreement with salt nature of the 
adducts observed by single crystal X-ray diffraction and confirmed by 13C 
CPMAS spectra. 
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Figure 1. 13C CPMAS spectra of LIDO, LIDO-OXA, LIDO-MOA, LIDO-SUA and 
LIDO-FUA co-crystals recorded at 100.64 MHz with a spinning speed of 12 kHz. 
 
 
Figure 2. 15N CPMAS spectra of LIDO, LIDO-OXA, LIDO-MOA, LIDO-SUA and 
LIDO-FUA co-crystals recorded at 40.56 MHz with a spinning speed of 12 kHz. 
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4. POLYMORPHS AND SALTS/CO-CRYSTALS SCREENING OF 
NALIDIXIC ACID 
4.1. Introduction 
 
Nalidixic acid (1) (1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-
carboxylic acid) is the first of the synthetic quinolone antibiotics. 1 is an 
antibacterial agent effective against both gram-positive and gram-negative 
bacteria. It is especially used in treating urinary tract infections, caused, for 
example, by Escherichia coli, Proteus, Shigella, Enterobacter, and Klebsiella.1  
 
N N CH3
CH3
OO
OH
Nalidixic Acid (1)  
Scheme 1. 
 
1, present in one crystal form (Form I) in CSD, was studied by polymorph and 
salt/co-crystal screening to identify new crystal forms. Experiments of 
evaporation and slurry at room temperature were performed in different solvents, 
and allowed the discovery of a new crystal form, named Form II, obtained by 
evaporation experiments at room temperature of a dichloromethane solution. The 
salt/co-crystal screening, performed using as coformer the bases listed in Table 2 
in Preface, allowed the discovery of two new salts/co-crystals of 1 with 
diethanolamine (DIETHAN) and pyrrolidine (PYR). The solid products obtained 
were characterized by X-ray powder diffraction (XRPD), differential scanning 
calorimetry (DSC), thermogravimetric analysis (TGA), FT-IR, Solid-State NMR 
(SS NMR) and single crystal X-ray diffraction (SC-XRD). The salt/co-crystal of 1 
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with pyrrolidine was also analyzed by evolved gas analysis (EGA) and variable 
temperature XRPD (VT-XRPD) that led to a new crystal form of 1 named Form 
III (same form delivered by Sigma Aldrich) characterized by different solid state 
techniques. The three crystal forms of 1 were also studied by interconversion 
experiments that allowed identify the only stable crystal form of 1: 1 Form I.  
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4.2. Experimental section 
 
4.2.1. Synthesis of 1 Form II 
 
1 Form II was obtained by evaporation of a dichloromethane solution of 1 bought 
from Sigma Aldrich (named 1 Form III). The solution was prepared dissolving 50 
mg of 1 as delivered in 4 mL of dichloromethane. The suspension was stirred for 
30 min until complete dissolution and filtered with Wathman filter 0.45µm. The 
solution was left to evaporate at room temperature. 
4.2.2. Synthesis of 1 – PYR 
 
1-PYR was crystallized by room temperature evaporation of a solution obtained 
dissolving stoichiometric amounts (1-1) of 1 and PYR in hot methanol 99.8%.  
4.2.3. Synthesis of 1 – DIETHAN 
 
1-DIETHAN was crystallized by room temperature evaporation of a solution 
obtained dissolving stoichiometric amounts (1-1) of 1 and DIETHAN in hot 
acetone.  
4.2.4. Synthesis of 1 Form III 
 
1 Form III (purchased by Sigma Aldrich) was obtained by VT-XRPD experiment 
performed on 1-PYR; Form III was obatined following loss of water and PYR by 
the salt/co-crystal 1-PYR, heated to approx. 120°C. 
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4.2.5. Thermal measuraments 
 
Thermogravimetric analyses were performed using a simultaneus STA 409 PC 
Luxx® Netzsch equipped with a thermocouple for the direct measurament of DSC 
signal, and a thermobalance for the measurament of TGA signal. The samples (5-
15 mg) were placed in aluminium pierced pans, and the heating was carried out at 
10°C min–1 in N2 atmosphere. 
Calorimetric measurements were performed using a DSC 200 F3 Maia® 
differential scanning calorimeter equipped with an intra-cooler. The samples (2–4 
mg) were placed in aluminium pierced pans, and the heating was carried out at 
10°C min–1 in N2 atmosphere.(See Supplementary material) 
4.2.6. X-Ray diffraction 
 
Single-crystal data were collected on an Oxford X’Calibur S CCD diffractometer 
equipped with a graphite monochromator (MoKα radiation, λ = 0.71073) and 
operated at room temperature. Data collection and refinement details are reported 
in ESI. The structure was solved by direct methods and refined by full-matrix 
least-squares on F2 with SHELX972a program package.  
A calculated XRPD pattern was generated for Cu radiation using Mercury v 1.4 
and the atomic coordinates, space group and unit cell parameter from the single 
crystal data. 
MERCURY and SCHAKAL99 2b were used for the graphical representation of 
the results and PLATON 2c was used for hydrogen bonding analysis. 
X-ray powder diffractograms were collected on a Panalytical X’Pert Pro 
automated Diffractometer equipped with X’Celerator, CuKα, using glass sample 
holder. The tube voltage and amperage were set to 40 kV and 40 mA, 
respectively. The program used for data collection was set to record only the data 
points within the range 2θ= 3° - 40°. VT-XRPD analyses were performed 
equipping the diffractometer with an Anton Paar TTK 450 low-temperature 
camera that is a non-ambient attachment for powder X-ray diffraction studies in 
reflection geometry from -193 °C to +450 °C. 
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4.2.7. FT-IR 
 
All FT-IR measurements were performed using Nicolet FT-IR 6700 Thermo 
Fischer equipped with ATR device. The analyses were performed on all samples 
and for each measurament 32 scans were performed (See Supplementary 
material). 
4.2.8. Solid-state Nuclear Magnetic Resonance (SS NMR) spectroscopy 
 
SS NMR experiments were recorded on a Bruker Avance II 400 instrument. The 
spactra were collected and interpreted by the Research Group of Prof. Roberto 
Gobetto at the University of Torino. 
4.2.9. Grinding experiments 
 
Grinding experiments were performed with a Retsch MM 200 grinder for 10 
minutes at a frequency of 30Hz, to verify the stability of crystal forms of 1. 
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4.3. Results and discussion 
 
In this work nalidixic acid was studied by polymorph and salt/co-crystal screening 
to identify new crystal forms. Experiments of evaporation and slurry at room 
temperature, performed in different solvents, led to the discovery of a new crystal 
form, named Form II, obtained by evaporation at room temperature from 
dichloromethane.  
The SC-XRD analysis of 1 Form II evidences the presence of four molecules of 1 
in the P21/n unit cell. As evidenced in the packing - Figure 1 – the structure is 
characterized by parallel planes while in Form I 3 – Figure 2- the molecules form 
zig-zag motifs.  
The correspondence of the structure determined by SC-XRD and that of bulk 
material, was checked by comparing the calculated pattern with the experimental 
one (Figure 3). 
 
Figure1. Packing of 1 Form II. 
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Figure2. Packing of 1 Form I. 
 
Figure3. Comparison between XRPD patterns of 1 Form II calculated (red line) and 
measured (blue line) 
1 Form II was also characterized by TGA, DSC, FT-IR and SS NMR. The DSC 
and SS NMR analyses led to the same results of Form I: the two crystal forms 
show the same SS NMR spectrum – Figure 4 - and the same DSC profile – Figure 
5 - with melting point at approx. 228.5°C 
1 Form II probably is an unstable crystalline form, which converts into Form I 
during the analyses. 
In fact, Form II heated to 150°C and measured by XRPD showed the XRPD 
pattern of Form I – Figure 6 - that at high temperature melt; this conversion is also 
observed by grinding experiment. 
This phenomenon is not observed during the DSC analysis, which shows only the 
endothermic peak associated to the melting of the compound (Form I). 
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Figure4a. Comparison between SS NMR spectra 13C of 1 Form I (a) and 1 Form II (b). 
 
Figure4b. Comparison between SS NMR spectra 15N of 1 Form I (a) and 1 Form II (b). 
(a) 
(b) 
(b) 
(a) 
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Figure5. Comparison between DSC profile of 1 Form I and 1 Form II. 
 
Figure6. Comparison between XRPD patterns of 1 Form I(blue line) and 1 Form II 
heated to 200°C (red line) 
 
 
  
 
 
 
 
Scheme 2.  
GRINDING 
FORM II 
HEATING 
FORM I 
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The salt/co-crystal screening, performed using as coformer the bases LISTED IN 
THE Table 2 in the Preface, allowed the discovery two new salts/co-crystals of 1: 
with diethanolamine (DIETHAN) and pyrrolidine (PYR). The powder obtained 
were characterized by XRPD and SC-XRD. 
The SC-XRD analysis of 1-DIETHAN evidences the presence of eight molecules 
of 1 and eight molecules of diethanolamine in the P-1 unit cell. As evidenced in 
the packing - Figure 7 – the structure is characterized by parallel planes held 
together by hydrogen bonds between diethanolamine molecules. Each plane is 
characterized by two chains of 1 and DIETAN alternatively held together through 
hydrogen bonds (Figure 8). 
 
Figure7. Packing of 1-DIETHAN: the structure is characterized by parallel planes held 
together by hydrogen bonds between diethanolamine molecules 
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Figure8. Packing of 1-DIETHAN: each plane are characterized by two chains of 1 and 
DIETAN alternatively held together through hydrogen bonds 
 
The correspondence of the structure determinate by SC-XRD and that of bulk 
material, was checked by comparing the calculated pattern with the experimental 
one (Figure 9). 
 
 
Figure9. Comparison between XRPD patterns of 1 DIETHAN calculated (black line) and 
measured (red line) 
 
The SC-XRD analysis of 1-PYR evidences the presence of two molecules of 1, 
two molecules of pyrrolidine and four molecules of water in the P-1 unit cell. As 
evidenced in the packing – Figure 10 - the structure is characterized by parallel 
planes held together by hydrogen bonds between chains and water molecules. 
Each plane is characterized by two chains of 1 and PYR alternatively held 
together through hydrogen bonds (Figure 11). 
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Figure10. Packing of 1-PYR:  the structure is characterized by parallel planes held 
together by hydrogen bonds between chains and water malecules.  
 
Figure11. Packing of 1-PYR: each plane are characterized by two chains of 1 and PYR 
alternatively held together through hydrogen bonds.  
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The correspondence of the structure determinate by SC-XRD and that of bulk 
material, was checked by comparing the calculated pattern with the experimental 
one (Figure 12). 
 
 
Figure12. Comparison between XRPD patterns of 1 PYR calculated (black line) and 
measured (red line) 
 
The salt/co-crystal of 1 with pyrrolidine was also analyzed by DSC, TGA, EGA, 
FT-IR, SS NMR and VT-XRPD. 
DSC profile – Figure 13 – evidences three endothermic events before of melt at 
228.4°C. The first two peaks are associated in TGA – Figure 14 – with a loss of 
pyrrolidine and water as showed by EGA analysis (figure 15a, 15b, 15c, 15d). 
The third peak is associated to a solid – solid transition of 1 that melts at 228.4°C 
(melting point of 1 Form I).  
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Figure 13. DSC profile of 1-PYR. 
 
Figure 14. TGA profile of 1-PYR 
Form III --->Form I 
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Figure 15a. 3D-EGA profile of 1-PYR 
	   	  
Pyrrolidine loss 
Water 
loss 
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Figure 15b. Kinetic of pyrrolidine and water lost. 
 
 
 
 
 
 
Figure 15c. Comparison between FT-IR spectrum obtained coadded region 
between 3 and 6 minutes and spectrum of water in data base: match 67.5% 
 
 
 
 
 
 
 
Figure 15d. Comparison between FT-IR spectrum obtained coadded region between 6 
and 10 minutes and spectrum of pyrrolidine in data base: match 68.3% 
 
 
Pyrrolidine loss 
Water loss 
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1-PYR was characterized by VT – XRPD. The sample was heated until melt at 
approx. 230°C and analyzed at different temperature summarized in the Table 1. 
 
FILE NAME TEMPERATURE RESULT 
1-PYR_30.0°C 30°C CO-CRYSTAL  
1-PYR_50.0°C 50°C CO-CRYSTAL 
1-PYR_76.6°C 76.6°C MIX 1 
1-PYR_85.5°C 85.5°C MIX 1 
1-PYR_93.0°C 93°C MIX 1 
1-PYR_105.7°C 105.7°C MIX2 
1-PYR_119.8°C 119.8°C MIX2 
1-PYR_143.1°C 143.1°C MIX2 
1-PYR_200°C 200°C 1 FORM I 
1-PYR_228°C 228°C AMORPHOUS+PEAK 
1-PYR_250°C 250°C AMORPHOUS 
Table 1. VT-XRPD steps of 1-PYR analysis. 
 
The sample shows the same pattern of the co-crystal until 50°C (Figure 16). 
 
 
Figure 16. Comparison between XRPD patterns of 1-PYR calculate (black line), sample 
analyzed at 30°C and at 50°C. 
 
  
168 
 
After 50°C the XRPD pattern begins to change: (Figure 17) the DSC at these 
temperatures evidences a double peak that in TGA-EGA corresponded to water 
and pyrrolidine losses in two steps. This pattern was also recorded analyzing a 
sample obtained by heating the salt/co-crystal to 85°C and also to 105°C in DSC 
with a heating rate of 10°C\min. 
 
 
Figure 17. Comparison between XRPD patterns of 1-PYR sample analyzed at 76.6°C, 
85.5°C, 93°C and sample heated to 85°C and 105°C by DSC. 
 
After 100°C the diffraction pattern recorded is the same of 1 Form III. This 
pattern was also recorded analyzing a sample obtained by heating the sample to 
120°C with a heating rate of 10°C\min (Figure 18) and left the sample at 120°C 
for 5 min to obtain the complete conversion of the co-crystal into 1 Form III 
(Figure 19). 
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Figure 18. Comparison between XRPD patterns of 1-PYR sample analyzed at 105.7°C, 
119.8°C, 143.1°C and sample heated to 120°C for 5 minutes. 
 
Figure 19. Comparison between XRPD patterns of 1-PYR heated to 120°C for 5 minutes 
and 1 as delivered by Sigma Aldrich (Form III) 
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After 120°C a solid - solid transition, associated in DSC with an endothermic 
peak, is observed: 1 Form III converts into 1 Form I. This pattern is also recorded 
analyzing a sample obtained by heating the salt/co-crystal to 170°C and 200°C 
with a heating rate of 10°C\min (Figure 20). 
 
Figure 20. Comparison between XRPD patterns of Form I (red line) and 1-PYR heated to 
200°C. 
 
1 Form III, obtained by VT-XRPD, shows the same XRPD pattern of 1 as 
delivered by Sigma Aldrich. The sample was also characterized by TGA, DSC, 
FT-IR and SS NMR. The DSC and SS NMR analyses led to the same results 
obtained for the Form I: the two crystal forms show the same SS NMR spectrum – 
Figure 21 - and the same DSC profile – Figure 22 - with melting point at approx. 
228.5°C. In the NMR spectrum of 1 Form III there are some peaks, probably of 
form III, that are too intense to be assigned. 
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Figure21. Comparison between SS NMR spectra 13C of 1 Form I (a), Form II (b) that 
during the analysis converts into Form I and 1 Form III (c). 
 
Figure22. Comparison between DSC profiles of 1 Form I and 1 Form III.  
(a) 
(b) 
(c) 
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Form III is an unstable crystalline form, which converts into Form I upon heating 
or grinding. 
In fact, Form III, heated to 200°C and then measured by XRPD, shows the XRPD 
pattern of Form I – Figure 23 - that at high temperature melts; this conversion was 
observed also by a grinding experiment. 
 
Figure23. Comparison between XRPD patterns of 1 Form I(blue line) and 1 Form III 
heated at 200°C (red line). 
 
 
 
 
 
 
 
Scheme 3. 
  
GRINDING 
FORM III 
HEATING 
FORM I 
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4.4. Conclusion 
 
In conclusion in this work we have subjected nalidixic acid to experiments of 
evaporation and slurry at room temperature and to salt/co-crystal screening using 
as coformer the bases listed in the table 2 in Preface. 
A new crystal form, named Form II, was obtained by evaporation at room 
temperature from dichloromethane. 
Salt/co-crystal screening led to the discovery of two new salts-co-crystals of 1 
with diethanolamine and pyrrolidine. 
The new form obtained were characterized by XRPD, DSC, TGA, FT-IR, SS 
NMR and SC-XRD. The salt/co-crystal of 1 with pyrrolidine was also analyzed 
by EGA and VT-XRPD, this last techinique allows us to identify a new crystal 
form of 1 named Form III. This new form shows the same XRPD pattern of the 
sample as delivered by Sigma Aldrich. The three crystal forms of 1 were also 
studied by interconversion experiments that led to identify the stable crystal form 
of 1: 1 Form I. In fact Form II and Form III convert into Form I through grinding 
and heating experiments.(Sheme 4) 
 
	  
Scheme 4  
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4.5. Supplementary Material 
 
---------------------------------------------------------------------------------------------------- 
Legenda 
1 = Nalidixic Acid 
1 - PYR = Nalidixic Acid – Pyrrolidine Salt/Co-crystal 
1 - DIETHAN = Nalidixic Acid – Diethanolamine Salt/Co-crystal 
---------------------------------------------------------------------------------------------------- 
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4.5.1. Crystal structure determination 
 
Crystal data and details of measurements are summarized in Table 1.  
Table 1. Crystal Data and Details of Measurements for compounds 1 Form II, 1-
PYR, 1-DIETHAN. 
Compound	   1	  Form	  II	   1-­‐PYR	   1-­‐DIETHAN	  
Formula	   C13	  H17	  N2	  O2	   C16	  H21	  N3	  O3	   C16	  H21	  N3	  O5	  
Mr	   232.23	   303.36	   335.36	  
system	   Monoclinic	   Triclinic	   Triclinic	  
space	  group	   P21/n	   P-­‐1	   P-­‐1	  
a	  [Å]	   10.072	   7(6)	   14.184	  
b	  [Å]	   7.041	   12(14)	   15.214	  
c	  [Å]	   15.229	   13(15)	   17.130	  
α 	  [°]	   90	   116(12)	   77.34	  
β 	  [°]	   96.30	   98(8)	   71.63	  
γ 	  [°]	   90	   102(9)	   74.81	  
V	  [Å³]	   1073.5	   903(1680)	   3347.7	  
Z	   4	   2	   4	  
dcalc	  [Mg	  mm-­‐3]	   1.443	   0.665	   1.116	  
F(000)	   500	   712	   324	  
µ (MoKα)	  	  [mm-­‐1]	   0.098	   0.050	   0.078	  
θmax	  [°]	   25	   25	   28.98	  
measured	  reflns	   4638	   30.776	   7374	  
unique	  reflns	   2435	   15197	   4103	  
refined	  parameters	   69	   901	   221	  
GOF	  on	  F²	   0.923	   0.688	   0.832	  
R1	  [on	  F,	  I	  >2σ (I)]	   0.0757	   0.0589	   0.0734	  
wR2(onF²,all	  data)	   0.2473	   0.1575	   0.1968	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4.5.2. Thermal measuraments 
	  
	  
	  
	   	  
1 Form I 
1 Form II 
1 Form III 
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4.5.3. FT-IR  
	  
	   	  
1 Form I 
1 Form III 
1 Form II 
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5. CHARACTERIZATION OF NEW SALTS AND CO-CRYSTAL 
OF SULFADIAZINE 
5.1. Introduction 
 
The sulfadiazine is a sulfonamide antibiotic. The sulfonamides are a class of 
antibacterial drugs used in treatment of urinary tract infection: they eliminate 
bacteria that cause infections stopping the production of folic acid inside the 
bacterial cell.1-4 
In this drug class the molecule contains multiple hydrogen bonds, donor and 
acceptor functions allowing the use of these molecules as co-crystallization 
partners with other drugs.5-6 
Sulfadiazine (Scheme 1), as all sulfonamide drugs, contains two important 
functional groups: one acidic moiety (NH) and one basic moiety (NH2). The 
amine nitrogen atom is able to gain a proton, while the amide nitrogen atom is 
able to release a proton under specific pH conditions.7 
NH2 S
O
O
NH
N
N
NH3
+
S
O
O
NH
N
N
NH2 S
O
O
N
-
N
N
3 3(+) 3(-)  
Scheme 1. 
Sulfadiazine is labeled as 3 in the neutral form, 3(-) in the anionic form and 3(+) 
in the cationic form (Scheme 1). 
Sulfadiazine, present in one crystal form (Form I) in the CSD8, was studied by 
polymorph and salt/co-crystal screening to identify new crystal forms.  
The salt/co-crystal screening was performed using as co-former the bases and 
acids listed in Table 2 in the Preface. 
The API was made to react with a co-former (solid or liquid) through different 
methods: crystallization by solution, grinding, kneading and solid-gas reactions.9 
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The screening allowed the discovery of six new salts and one co-crystal 
characterized by X-ray powder diffraction (XRPD), differential scanning 
calorimetry (DSC), thermogravimetric analysis (TGA), evolved gas analysis 
(EGA), FT-IR. The salts of 3 with pyrrolidine (PYR) and methanesulfonic acid 
(MSA) were also characterized by single crystal X-ray diffraction (SC-XRD). 
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5.2. Experimental section 
 
All reactants were purchased from Sigma Aldrich and used without further 
purification. Reagent grade solvents and doubly-distilled water were used.  
5.2.1. Solution synthesis 
 
All salts/co-crystals were crystallized by room temperature evaporation of a 
solution obtained dissolving a stoichiometric mixture (1-1) of 3 and acid or base 
in hot acetone.  
5.2.2. Mechanochemistry 
 
The salts of 3 with PYR, KOH and H3PO4 were quantitatively obtained as 
polycrystalline materials by grinding or kneading experiments (3 and acid or base 
are in a 1:1 ratio). The experiments were performed with a Retsch MM 200 
grinder for 15 minutes at frequency of 30Hz. 
5.2.3. Solid-gas reaction 
 
The salt/co-crystal of 3 with formic acid was also obtained after 3 days of 
exposure to the acid vapor. 
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5.2.4. Thermal measurements 
 
Thermogravimetric analyses were performed using a simultaneus STA 409 PC 
Luxx® Netzsch equipped with a thermocouple for the direct measurament of DSC 
signal, and a thermobalance for the measurement of the TGA signal. The samples 
(5-15 mg) were placed in aluminium pierced pans, and the heating was carried out 
at 10°C min–1 in N2 atmosphere (See supplementary material). 
Calorimetric measurements were performed using a DSC 200 F3 Maia® 
differential scanning calorimeter equipped with an intra-cooler. The samples (2–4 
mg) were placed in aluminium pierced pans, and the heating was carried out at 
10°C min–1 in N2 atmosphere. (See supplementary material). 
5.2.5. Single crystal X-Ray diffraction 
 
Single-crystal data were collected on an Oxford X’Calibur S CCD diffractometer 
equipped with a graphite monochromator (MoKα radiation, λ = 0.71073) and 
operated at room temperature. The structure was solved by direct methods and 
refined by full-matrix least-squares on F2 with SHELX9710a program package.  
A calculated XRPD pattern was generated for Cu radiation using Mercury v 1.4 
and the atomic coordinates, space group, and unit cell parameters from the single 
crystal data. 
MERCURY and SCHAKAL9910b were used for the graphical representation of 
the results and PLATON10c was used for hydrogen bonding analysis. 
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5.2.6. Powder X-Ray diffraction 
 
Diffraction patterns from 3° to 40° in 2θ were collected on a PANalytical 
diffractometer with Bragg–Brentano geometry (Cu Kα radiation, detector: 
X'celerator, step size Δ2θ = 0.0167°, counting time per step = 20 s), using a glass 
sample holder. The tube voltage and amperage were set to 40 kV and 40 mA, 
respectively. 
5.2.7. FT-IR 
 
All FT-IR measurements were performed using Nicolet FT-IR 6700 Thermo 
Fischer equipped with ATR device. The analyses were performed on all samples 
and for each measurement 32 scans were recorded (See supplementary material). 
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5.3. Results and discussion 
 
In this work 3 was studied by polymorph and salt/co-crystal screening to identify 
new crystal forms.  
The screening allowed the discovery of six salts and one co-crystal (with formic 
acid) – Scheme 2, 3- characterized by X-ray powder diffraction (XRPD), 
differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
evolved gas analysis (EGA), FT-IR (See supplementary material). The salts of 3 
with PYR and MSA were also characterized by single crystal X-ray diffraction 
(SC-XRD). 
 
 
Scheme 2. Reaction of 3 with acids. 
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Scheme 3. Reaction of 3 with bases. 
 
The API was made to react with a co-former (solid or liquid) through different 
methods: crystallization from solution, grinding, kneading and solid-gas reactions. 
The results obtained are summarized in Table 1. 
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Table 1. Methods used to obtained salts or co-crystals (the co-crystal 3c was also 
obtained by solid-gas reaction. 
SAMPLE  SOLUTION 
SYNTHESIS  
GRINDING-
KNEADING 
3a SALT - 
3b  SALT SALT 
3c  COCRYSTAL - 
3d SALT - 
3e SALT SALT 
3f  SALT - 
3g SALT SALT 
 
In the figure 1 is showed a comparison of diffraction patterns of salts and co-
crystal obtained by screening and pattern of 3 for comparison. 
 
 
Figure 1 .Comparison between diffraction patterns of different salts and co-
crystals obtained by screening. 
Differential scanning calorimetry was used to measure the melting point of all 
compounds and to detect the presence of additional crystalline phases.  
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Thermogravimetric analysis (TGA) was used to measure possible solvent loss. 
This tecnique was associated with evolved gas analysis (EGA) that measured 
IR spectra  and the kinetic profile of solvent loss during the TGA. 
In Table 2 are summarized the onset and the solvent loss measured with EGA of 3 
and of new compounds synthesized. 
 
Table 2 
Sample  Onset(°C)  Solvent Loss  
3 261.8 - 
3a 63.7 
159.5 
Water- HCl 
3b  139.7 - 
3c  263.2 Formic acid  
3d 27.4 
259.7 
- 
3e 52.3 
93.2 
166.9 
260 
Water 
3g 200.7 Pyrrolidine 
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The SC-XRD analysis of 3g evidences the presence of four ions of 3(-) and four 
pyrrolidine cations  in the Pna21 unit cell. As evidenced in the Figure 2 the 
compound obtained is a salt, in fact, PYR is in cationic form and the 3 is in 
anionic form 3(-): there is the proton transfer from the amide (N1) group of 3 to 
N5 of PYR that forms an hydrogen bond with N1 of one molecule of 3(-) and two 
hydrogen bonds with N4 and O2 of another molecule of 3(-). The amino group 
(N2) of 3(-) forms a hydrogen bond with O1 of another molecule of 3(-). 
 
 
Figure 2. Hydrogen bonds in 3g salt. 
 
The correspondence, of the structure, determined by SC-XRD, and that of bulk 
material was checked by comparing the calculated pattern with the experimental 
one (Figure 3).  
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Figure 3. Comparison between XRD patterns of 3g salt calculate (black line) and 
experimental (red line). 
 
The SC-XRD analysis of 3f evidences the presence of two ions 3(+), two 
methanesulfonate anions and two water molecules in P-1 unit cell. As evidenced 
in figure 4 the compound obtained is a salt, in fact, the MSA is in anionic form 
and the 3 is in cationic form 3(+): there is the proton transfer from the acid to the 
amino (N1) group of 3. N1 amino group of 3(+) form three hydrogen bond with 
O3, O4 and O5 of three molecules of acid and one hydrogen bond with a molecule 
of water that forms two hydrogen bonds with two molecules of acid. N2 and N4 
groups of 3(+) form two hydrogen bonds with another ions of 3(+). 
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Figure 4. Hydrogen bonds in 3f salt. 
 
The correspondence, of the structure, determined by SC-XRD, and that of bulk 
material was checked by comparing the calculated pattern with the experimental 
one (Figure 5). 
 
Figure 5. Comparison between XRD patterns of 3f salt calculate (black line) and 
experimental (red line).  
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Crystal data and details of measurements for compounds 3g and 3f are 
summarized in table 3. 
Table 3. Crystal data of 3 salts. 
compound 3g 3f 
Formula C14 H19 N5 O2 S C11 H14 N4 O5 S2 
Mr 321.40 346.38 
system ORTHOROMBIC TRICLINIC  
space group Pna21 P-1 
a [Å] 10.9847(5) 5(6) 
b [Å] 12.8697(5) 9(1) 
c [Å] 10.7788(4) 16(2) 
α  [°] 90 82(1) 
β  [°] 90 86(1) 
γ[°] 90 78(1) 
V [Å³] 1523.80(1) 784.148 
Z 4 2 
dcalc 1.401 1.467 
F(000) 680 360 
measured reflns 4366 5833 
unique reflns 2255 3502 
refined parameters 216 268 
GOF on F² 0.931 0.911 
R1 [on F, I>2σ(I)] 0.0334 0.0439 
wR2(onF²,all data) 0.0670 0.1047 
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5.4. Conclusion 
 
In this work 3 was studied by polymorph and salt/co-crystal screening to identify 
new crystal forms. The API was made to react with a co-former (solid or liquid) 
through different methods: crystallization by solution, grinding, kneading and 
solid-gas reactions The screening allowed the discovery of six salts and one co-
crystal (3c with formic acid) – Scheme 4, 5 - characterized by X-ray powder 
diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric 
analysis (TGA), evolved gas analysis (EGA), FT-IR (See supplementary 
material). The salts 3f and 3g were also characterized by single crystal X-ray 
diffraction (SC-XRD). 
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Scheme 4. Reaction of 3 with acids. 
 
 
Scheme 5. Reaction of 3 with bases. 
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5.5. Supplementary Material 
 
-------------------------------------------------------------------------------------------- 
Legenda 
3 = SULFADIAZINE 
3a = Salt obtained by reaction of 3 with HCl  
3b= Salt obtained by reaction of 3 with H3PO4 
3c= Co-crystal obtained by reaction of 3 with formic acid 
3d= Salt obtained by reaction of 3 with NaOH 
3e= Salt obtained by reaction of 3 with KOH 
3g= Salt obtained by reaction of 3 with pyrrolidine 
-------------------------------------------------------------------------------------------- 
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5.5.1. Thermal measuraments 
  
3 
3a 
197 
 
 
 
  
3b 
3c 
198 
 
 
 
  
3d 
3e 
199 
 
 
 
 
 
 
 
 
 
 
 
 
   
3g 
3 
200 
 
 
 
 
 
 
 
 
 
 
 
 
  
3a 
3b 
201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
3c 
3d 
202 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
3e 
3g 
203 
 
5.5.2. FT-IR 
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